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1.1 Head and neck squamous cell carcinoma (HNSCC)  
1.1.1 Definition and incidence of HNSCC 
Tumours of the head and neck region develop from the mucosal lining of the upper 
aerodigestive tract and include malignant tumours of the nasal cavity and the paranasal 
sinuses, the nasopharynx, the hypopharynx, the larynx, the trachea, the oral cavity and the 
oropharynx (Figure 1.1). Histologically, most of malignant tumours of the head and neck 
region are squamous cell carcinomas (SCC) (Epstein et al. 2008). The remainder are 
adenocarcinomas, adenoid cystic carcinomas, non-Hodgkin’s lymphomas, melanomas and 












Figure 1.1: Anatomy of the head and neck illustrating the location of paranasal sinuses, na sal 
cavity, oral cavity, tongue, salivary glands, larynx, and pharynx  (including nasopharynx, 






Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common carcinoma in 
the Western world (Ferlay et al. 2008). In 2002, the World Health Organization (WHO) 
estimated that there were about 600,000 new cases of head and neck cancer each year which 
affected primarily the oral cavity (389,000 cases), the larynx (160,000) and the pharynx 
(65,000) and 300,000 persons died from these cancers each year worldwide (Boyle and Levin 
2008). 
Recently, a marked increase in the prevalence of tonsillar and oropharyngeal carcinoma 
associated with human papillomavirus (HPV) has been observed. In a population-based study, 
the incidence of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) had 
increased by 225% between 1988 and 2004, while the incidence of HPV-negative 
oropharyngeal carcinoma had decreased by 50% in the same period (Chaturvedi et al. 2011). 
1.1.2 Risk factors for HNSCC 
HNSCC is primarily caused by exposure to alcohol and tobacco products. Tobacco-related-
products include cigarettes, cigars, and smokeless tobacco. The combination of both alcohol 
and tobacco increases the risk for HNSCC 13-fold compared with exposure to each agent 
alone (Gillison 2007). Smoking and alcohol have historically been the classic risk factors for 
approximately 42% of head and neck cancers. However, despite a shift in HNSCC 
epidemiology in recent decades, the incidence of oropharyngeal cancer has risen among 
younger persons with little or no history of smoking (Mehta et al. 2010, Cmelak 2012). It is 
now known that these tumours are caused by sexual transmitted HPV (Marur et al. 2010). 
HPV-associated oral cancers generally arise from the lingual and palatine tonsils in the 
oropharynx (Gillison 2004).  
Besides sexual behaviour, exposure to marijuana was also strongly associated with the high-
risk type of HPV infection, HPV-16 (Gillison et al. 2008). HPV infection in combination with 
alcohol and tobacco consumption may act synergistically to increase the HNSCC risk (Smith 
et al. 1998). Besides the above mentioned exogenous risk factors, oral hygiene (Guha et al. 
2007), certain inherited disorders and also a more general genetic susceptibility may 





1.1.3 Prognostic factors in HNSCC patients 
There are numerous factors which affect the prognosis of HNSCC. The primary site of tumour 
and the TNM (tumour, node, and metastasis) stage are the most important prognostic factors 
(Kowalski and Carvalho 2001). In addition, the infection with HPV has been known to be of 
significant prognostic importance and HPV-positive HNSCC patients showed a better 
prognosis (Gillison et al. 2008). 
Molecular markers of prognosis have been studied but none has yet entered routine clinical 
reporting. Several candidates have been suggested. Based on a large study by Poeta et al.,  
patients with tumour expressing wild-type p53 had better five-year overall survival (OS) 
compared to tumours which were positive for p53 mutation (Poeta et al. 2007). In a meta-
analysis of 12 studies, the tumours with expression of vascular endothelial growth factor 
(VEGF) had twice the risk of specific cancer mortality (Kyzas et al. 2005). Some other 
studies showed that tumour hypoxia, in particular the increased expression of hypoxia-
inducible factor-1α (HIF-1 α), associated with adverse prognosis and local tumour 
aggressiveness (Aebersold et al. 2001, Yeo et al. 2004). Moreover, patients with high 
expression of epidermal growth factor receptor (EGFR) had poor prognosis and has also been 
linked to radiotherapy and drug resistance (Dai et al. 2005, Silva et al. 2007). The role of the 
CXCL12/CXCR4 axis in HNSCC has been investigated in some studies, and for the subgroup 
of oral squamous cell carcinoma (OSCC) a correlation between CXCR4 expression and OS 
was described (Salcedo et al. 1999, Katayama et al. 2005, Uchida et al. 2007), as well as a 
correlation between CXCR4 expression and lymph node or distant metastasis (Salcedo et al. 
1999, Katayama et al. 2005, Ishikawa et al. 2006, Keeley et al. 2010, Ueda et al. 2010). 
CXCL12 expression was found to be higher in metastatic lymph nodes than in the primary 
tumour, and the intra-tumour CXCL12 levels correlated with the OS (Clatot et al. 2011). 
Although many biomarkers correlate with metastasis and mortality of HNSCC, none is 
appropriately independent or has prognostic value to be used routinely. 
1.1.4 Survival of HNSCC patients and tumour recurrence 
Despite improvements in surgical techniques, chemotherapy (CT) and radiotherapy (RT), the 
five-year survival rate for patients with HNSCC has remained relatively stable at less than 





survival rates are mainly due to a disease recurrence, which can lead to treatment failure and 
subsequent death. After tumour resection minimal leftover of tumour cells may remain 
adjacent to the lesion that are undetectable during histopathological assessment (van Houten 
et al. 2002) and cancer cells that were not removed are still present during post-treatment, 
which can lead to a recurrence of the disease. 
Early detection of HNSCC is the most critical step in reducing morbidity and mortality. About 
one third of the patients present with stage I or stage II disease have a cure rate of up to 90% 
and 70%, respectively (Argiris et al. 2008). After surgery, patients with late-stage disease 
often present with a local recurrence or a distant tumour
 
(Argiris et al. 2008). In advanced 
HNSCC cases the tumour can metastasise to the lymph nodes causing cancer cell growth in 
the neck
 
(Argiris et al. 2008). The survival rate of head and neck cancer patients decreases by 
at least 50% if lymph nodes positive for the tumour
 
are detected (Sanderson and Ironside 
2002). The most common anatomical sites of distant metastases are the lungs, followed by 
bones and the liver (Leon et al. 2000, Ferlito et al. 2001).  
Most HNSCC patients present with cervical lymph node metastasis (Beasley et al. 2002). As 
an independent prognostic factor, cervical lymph node metastasis has a great impact on the 
OS of patients with HNSCC (Burusapat et al. 2015). Cervical metastasis is perhaps the most 
significant oncological factor in the prognosis of HNSCC, and if they are detected and treated 
early have a favourable prognosis (Burusapat et al. 2015). However, once distant metastases 
occur, the patients have an extremely poor prognosis. The mean survival time after the 
diagnosis of distant metastases is about six months and 90% of patients die within two years 
(Calhoun et al. 1994). 
1.1.5 Treatment of HNSCC 
The management of patients with HNSCC is currently a significant oncological challenge. 
The overall aim is to achieve increasingly higher survival rates. The consequences of 
treatment failure that often occur in late-stage disease such as facial disfigurement, loss of 
speech and impairment of the vital survival functions of swallowing and breathing can cause 
serious medical and psychosocial problems. Because of these psychosocial stress factors, the 





The bases of treatment of HNSCC are surgery, RT, CT and to a lesser extent novel targeted 
therapies. Treatment modalities vary depending on the stage of the disease at the time of 
diagnosis and tumour histology (Chin et al. 2006). For early stage HNSCC without regional 
metastases, one treatment modality is sufficient, usually wide surgical excision or curative RT 
(Chin et al. 2006, Pai and Westra 2009). However, approximately 60% of the patients are 
diagnosed in stage III. For late-stage primary tumours with or without regional metastases, 
treatment usually consists of a combination of surgery and post-operative RT or 
radiochemotherapy (RCT) (Chin et al. 2006, Perez-Ordonez et al. 2006, Pai and Westra 
2009). However, when comparing the evidences available to determine the optimal 
therapeutic approach, it is clear that no single therapeutic approach offers a clear benefit over 
the others (Corvo 2007). Actually, ten percent of the patients presenting with metastases 
(Horner and Krapcho 2009) and about 50% of the patients treated for advanced disease will 
have a recurrence (Clark et al. 2005, Boyle and Levin 2008).  
Aside from the outcome, the quality of life is also influenced by the therapeutic approaches. 
The long-term side-effects affecting the quality of life vary depending on the treatment, i.e. 
RT, CT or both. For instance, irradiation frequently causes organ or hematotoxicity. In studies 
on patients with inoperable HNSCC without distant metastases Wolff et al. showed a 
significant connection between high-grade acute organ toxicity (HGAOT) during primary 
R(C)T and OS and locoregional tumour control, compared to patients undergoing these 
treatments without developing acute organ toxicity (Wolff et al. 2010a). The same significant 
correlation was also observed for patients with locally advanced HNSCC when were treated 
with adjuvant RCT (Wolff et al. 2011b). In a study on locally advanced rectal cancer Wolff 
and co-workers also reported a statistically significant correlation between HGAOT during 
preoperative RCT and complete tumour regression (Wolff et al. 2010b). Similar results were 
also observed in patients with breast cancer by Kuhnt et al. (Kuhnt et al. 1998). In addition, 
Wolff et al. showed a significant correlation between HGAOT and OS and locoregional 
control in patients with anal carcinoma (Wolff et al. 2010c). They reported that patients with 
HGAOT have a five-year OS rate of 97% compared to 30% for patients without HGAOT.  
Although the differences in the biological and clinical characteristics of HPV-associated 
HNSCC and HPV-negative tumours have been known for several years, the treatment 
approaches have not taken this into account in the case of HPV-positive HNSCC patients. 
Some retrospective studies reported that patients with HPV-positive tumours have a better 





al. 2002, Klussmann et al. 2003, Hafkamp et al. 2008) regardless of the employed therapy 
(Fakhry et al. 2008, Fallai et al. 2009, Lassen et al. 2009, Ang et al. 2010).  
There are still no sufficient prospective clinical trials clarifying whether changes in treatment 
modalities, such as reducing the intensity of the therapy, can influence the quality of life of 
those patients with HPV-positive tumours and at the same time can maintain or further 
improve survival rates. 
1.2 Active HPV-participation in HNSCC 
1.2.1 Human Papillomavirus (HPV) 
HPV are small, non-enveloped, epitheliotropic, circular double-stranded DNA viruses 
(Schiffman et al. 2007). There are more than 150 different known types of HPV (Bernard 
2010) that can be divided into two groups according to their risk for humans, i.e. “high-risk” 
HPV types (potentially oncogenic) and “low-risk” HPV types (rarely or never oncogenic) 
(Chow et al. 2010). According to the literature the group of high-risk HPV types includes 
HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 (IARC 2011). Particularly HPV-16 and 
18 are known to cause malignant transformation of normal cervical epithelial cells (Clifford et 
al. 2003). Accordingly, some studies analysed the role of HPV as an aetiological agent in a 
subset of HNSCC (Kreimer et al. 2005, Strati and Lambert 2007, Allen et al. 2010). Based on 
currently available evidence, oral HPV infection is sexually transmitted to the upper 
aerodigestive tract, by oral genital contact (D'Souza et al. 2007). For instance, Anaya-
Saavedra et al. in a study of 62 patients and 248 controls showed that the presence of HPV 
DNA in the oral cavity was significantly related with a younger age of first sexual contact and 
increasing numbers of lifetime sexual partners (Anaya-Saavedra et al. 2008). In addition, 
HPV-6 and HPV-11 as low-risk HPV types have also been detected in some HNSCC patients, 
which may indicate that these low-risk HPV types are not truly benign (Kreimer et al. 2005). 
1.2.2 Molecular evidence for the role of HPV in HNSCC tumour progression 
The HPV genome is approximately 8 kbp in length with eight open reading frames (ORFs), 
which encode the early genes (E1, E2, E4, E5, E6 and E7) and two late genes (L1 and L2) 





transcription or the regulatory function of the HPV genome, the L1 and L2 genes convey the 
information for the capsid proteins. The transcription of the early and late genes is controlled 
by the non-coding LCR (long control region), which contains the origin of replication, 
promoters, binding sites for core transcription factors, enhancer and repressor proteins (Chow 
et al. 2010) (Fig. 1.2).  
After entering the host cell, the E1 and E2 genes, which are required for the replication of 
viral DNA, are expressed (Motoyama and Ladines-Llave 2004, Zur Hausen 2006) to permit 
an episomal form of the viral genome to be maintained (Wilson et al. 2002). HPV E4 is 
expressed at a later phase of the viral life cycle, when the virus particles assembled (Zur 
 
 
Figure 1.2: The organization of HPV-16. The HPV-16 DNA genome (7905 bp in size, circular 
double-stranded DNA) consists of two coding regions of early genes (E1 -E7; yellow), which are 
expressed early in the viral life cycle and the late genes (L1 and L2; green) that encode the structural 
capsid proteins. Two important proteins, E6 and E7 are known as oncoproteins. The E6 protein 
promotes cell proliferation and also inhibits apoptosis. The E7 protein is the main cause of the 
transformational potential of special high-risk HPV types. The non-coding region, the long control 
region (LCR), is located between L1 and E6 ORFs, which is responsible for the regulation of DNA 






Hausen 2006). The E6 and E7 proteins are the critical molecules in viral replication and both 
are the major mediators of carcinogenesis in the high-risk HPV types. The L1 and L2 proteins 
are expressed late in the infection cycle and spontaneously form an icosahedral virus capsid 
consisting of 72 capsomeres (Baker et al. 1991). Before this happens it comes to the 
conformation of the virions, and completed viruses are then released from the outer layer of 
the epithelium (Hummel and Hudson 1992). 
The oncogenic E6 and E7 proteins are responsible for the progression of malignancy (Goia et 
al. 2010). The E6 protein of the high-risk HPV types, but not of the low-risk HPV types, has 
oncogenic potential. HNSCC with active HPV participation usually has an intact p53 
gene(Balz et al. 2003). However, the synthesised protein is inactivated by the E6 oncoprotein. 
As a result, cell proliferation will be favoured and apoptosis inhibited. Carcinomas without 
HPV involvement, however, often show mutations in the p53 locus (Wiest et al. 2002, 
Braakhuis et al. 2004) and are associated to a greater degree with tobacco and alcohol 
consumption (Brennan et al. 1995). However, the inactivation of p53 in HNSCC have no 
distinct significance role for tumour progression and prognosis (Bosch et al. 2004). 
Retinoblastoma protein (pRb), which is inactivated by the viral oncoprotein E7, also plays a 
central role in the carcinogenesis of HPV-associated HNSCC. However, a loss of function of 
the Rb gene, e.g. by mutation in HPV-negative HNSCC, is rare (Todd et al. 2002). If pRb is 
inactivated by HPV E7, the transcription factor E2F is permanently released to promote cell 
cycle progression (Dyson et al. 1989). This pathway is firmly regulated by a set of cyclin-
dependent kinase inhibitors, among them p16
INK4A
. In addition, the Rb protein is important for 
the negative regulation of p16
INK4A
 (Reimers et al. 2007). In functionally inactivated pRb 
cells, p16
INK4A 
is also synthesised in large quantities without any intervention in the cell cycle 
inhibition (Figure 1.3). Overexpression of p16
INK4A
 has often been used as an important 
marker for HPV E7 activity, and increased expression of p16
INK4A
 is frequently found in 
HPV-associated HNSCC (Klussmann et al. 2003, Weinberger et al. 2006, Reimers et al. 
2007, O’Regan et al. 2008). Since p16
INK4A
 overexpression is very seldomly seen in HPV-





positivity is considered to be a surrogate marker for HPV-





1.3 The role of the microenvironment in tumour development 
It has become obvious that changes in the stromal microenvironment are important for the 
homeostasis of normal tissues and also for the progression, migration, invasion and metastasis 
of tumour cells (Bissell et al. 2002). Moreover, the secreted extracellular matrix that includes 
inhibitors, proteases, chemokines and growth factors affects both tumour and stromal cell 
behaviour (Mueller and Fusenig 2004). Interestingly, experiments by Polyak et al. have 
revealed that the initial modification leading to carcinoma development can occur either in 
epithelial cells or in adjacent stromal cells (Polyak et al. 2009). Furthermore, the stroma can 
both suppress and induce cancer progression (Bissell and Hines 2011).  
 
 
Figure 1.3: Schematic view of HPV infection of a mucosal cell.  The human pathogenic virus enters 
the host cell by endocytosis, after which it causes a persisting infection as a viral episome or integrates 
into the genome of the host cell. From both forms of the viral DNA, viral oncoprote ins such as E6 and 
E7 are expressed. This causes degradation of p53 and inhibition of pRb, respectively. E7 oncoprotein 
with dissociation of pRb and E2F causes a subsequent up -regulation of p16 INK4A. Various methods are 
established to detect HPV DNA, E6 and E7 oncogene or p16 INK4A expression with regard to the stage of 





The tumour microenvironment is composed of a non-cellular fraction consisting of collagen, 
elastin, fibronectin, fibrin, and a very heterogeneous cellular fraction. The latter mainly 
contains fibroblasts, epithelial cells and immune cells, which interact with each other and the 
adjacent tumour cells (Li et al. 2007). The interaction between tumour cells and stroma occurs 
in various ways. Tumour cells can influence the stroma directly by changing the surrounding 
extracellular matrix or indirectly by modulating the metabolism of stromal cells (Zigrino et al. 
2005). These direct or indirect effects are mediated by the release of soluble factors such as 
chemotactic factors by the tumour cells, which in consequence cause an active change in the 
cellular composition of the stroma (Zigrino et al. 2005). The stroma cells in turn affect the 
progression and the survival of the tumour cells by paracrine secretion. Furthermore, this 
cellular communication alters the cellular and molecular composition of a particular tumour 
microenvironment in a manner that supports cancer cell proliferation and increases the 
invasiveness and metastatic potential of tumour cells (Bhowmick and Moses 2005, Li et al. 
2007, Itano et al. 2008). Some stroma-derived soluble cytokines, such as tumour necrosis 
factor-α (TNF-α) and interleukin-6 (IL-6), may be exploited by the tumour cells in a manner 
that supports anti-apoptotic mechanisms and even fosters intratumoural angiogenesis, thus 
promoting local and systemic tumour dissemination or metastasis (Szlosarek et al. 2006, 
Knupfer and Preiss 2007).  
The proportion of the stroma varies from tumour to tumour, but in any case it plays a crucial 
role in tumour progression, and significantly influences the growth, invasiveness, metastatic 
behaviour and also the sensitivity of the tumour to the various types of therapy (Fukumura 
and Jain 2007, Tse and Kalluri 2007). Fibroblasts and immune cells represent a significant 
portion of the tumour environment, which by producing a broad spectrum of growth factors 
and chemokines can directly stimulate tumour cell growth and even their own precursor cells, 
so that they themselves respond with abnormal growth and proliferation pattern (Li et al. 
2007). It is also notable that the interstitial tissue of a solid tumour may exert an anti-
tumourigenic influence on the tumour cells. Particularly, interferon-γ (IFN-γ), a stroma-
derived soluble cytokine, is an example for reducing tumour mass formation by controlling 





1.3.1 Metastasis: a multistep process  
The important role of the stroma in the development of metastatic tumours was described 
towards the end of 20
th
 century. At that time the idea was established that tumours, depending 
on their nature, metastasise into some preferred organs. The conclusive role was ascribed to 
the microenvironment and can be read in Paget’s “Seed and Soil” hypothesis (Paget 1989). To 
recognize the importance of the development of metastases in tumour progression, we have to 
bear in mind that 90% of deaths from cancers are due to metastases (Sporn 1996). Since 
metastasis is the foremost cause of cancer morbidity and mortality (Jemal et al. 2010), 
understanding the development of metastasis is important to improve the patients’ survival 
rate. 
Metastasis is a multistep process, which is based on the complex interaction of various 
molecular mechanisms and a highly organized, non-randomized and organ-specific process 
(Howell and Grandis 2005). In a first step, by changes in cell-cell contacts and loss of 
adhesion, some cells from the primary tumours succeed in evading from the solid structure 
(Chambers 2001). Later, the invasive tumour cells individually or in a cell assembly become 
motile and either penetrate the blood system or enter a lymphatic vessel, a process which is 
referred to intravasation (Chambers 2001, Bogenrieder and Herlyn 2003, Howell and Grandis 
2005). In this step, proteolysis of the extracellular matrix and the directed migration/invasion 
of tumour cells play an essential role (Bogenrieder and Herlyn 2003). In a third step, the 
migrating tumour cells follow the routes of lymph or blood vessels until they reach a 
secondary organ, e.g. a lymph node, or lung or liver tissue, which they can invade (Figure 
1.4). After successful extravasation in the target organ, the invasive capacity, proliferation and 
angiogenesis of those cancer cells are key processes for the development of a metastasis 
(Chambers 2001, Bogenrieder and Herlyn 2003, Howell and Grandis 2005). Subsequently, 
those tumour cells can start to colonize the new environment to form a secondary neoplasm, 
or they might deactivate the cell cycle for some time which causes a delayed metastatic 
relapse (Hedley and Chambers 2009). Importantly, effective colonisation by migrated primary 
tumour cells in target organs crucially depends on the interaction between the tumour cells 





Although a number of known physiological molecules are important for stimulating tumour 
cell motility and invasion, the exact molecular mechanisms that mediate the directed 
migration/metastasis of tumour cells into a specific organ are largely unknown (Bogenrieder 
and Herlyn 2003, Wong and Hynes 2006).  
1.3.1.1 Three theories of seeding and colonisation in organ-specific metastasis 
Organ selectivity of migrated primary tumour cells is recognised for seeding and colonisation. 
Breast cancer cells for instance prefer to metastasise to the bones, the lungs and the brain, 
whereas colorectal cancer cells commonly colonise the liver. Three different concepts have 
been proposed that attempt to explain organ-specific metastasis.  
 
 
Figure 1.4: Schematic diagram of the metastatic cascade.  Some malignant tumour cells break away 
from the primary tumour and leave their primary site of growth (local invasion, intravasation) followed 
by systemic translocation (survival in ci rculation, arrest at a distant organ site, extravasation) and last 
but not least adjust to survive in distant tissue (metastatic formation). This figure was taken from 





Growth factor theory 
This theory assumes that tumour cells can theoretically “seed” into all organs via the 
circulation. However, they can only colonise such organs that provide them with the 
appropriate growth factors (Chambers 2001).   
Adhesion theory 
This theory states that the extravasation of tumour cells is controlled by certain adhesion 
molecules, which are expressed by the endothelium in an organ-specific manner (Qian et al. 
2001). 
Chemoattractant theory  
This theory assumes that tumour cells can metastasise to certain organs on the basis of 
chemokine gradients, which means that the tendency for specific organs is determined by the 
local expression of chemoattractants (Figure 1.5) (Liotta 2001, Müller et al. 2001, Homey et 
al. 2002).  
Chemokines can attract and activate various. For which reason migrating tumour cells that 
express special chemokine receptors are guided to the site of future metastasis formation as a 
consequence of chemokine gradients. For instance, breast cancer patients that express the 
chemokine receptor CXCR4 have a poor prognosis (Zlotnik 2008). It has been shown that 
CXCR4-positive tumour cells migrate to organs that naturally express high quantities of its 
ligand, CXCL12 (also known as SDF-1; stromal cell-derived factor-1), such as lung, liver and 
bones (Figure 1.5). Actin polymerization and also pseudopod formation are the results of 
CXCR4-mediated signalling and the cause of invasion of primary tumour cells (Müller et al. 
2001). In addition, Müller et al. showed that in a xenograft mouse model neutralising  







Cytokines are 15 to 25 kDa peptide mediators that are involved in paracrine and autocrine cell 
communication. Chemokines are small signal proteins with highly conserved three-
dimensional structures and members of the large family of chemotactic cytokines that can be 
synthesized by almost all cells in the human organism after stimulation.  
 
 
Figure 1.5: The functional relevance of chemokines and chemokine receptors in organ -specific 
metastasis according to the findings of Müller et al. (Müller et al. 2001). Malignantly transformed 
breast epithelial cells possess a highly chemokine receptor-enriched surface; such as CXCR4. 
Chemokines that bind to these kinds of receptors with a high affinity, e.g. CXCL12, are produced in 
high quantities only by certain organs such as bone marrow, liver and lung. Once malignant primary 
breast cancer cells locally invade the vascular and lymphatic system, they are attracted to organs 
producing high amounts of chemokines. This hypothesis reflects the relative organ -specific metastasis 





Chemokines are categorized into four main families, CL, CCL, CXCL and CX3CL, based on 
the number and location of cysteine residues at the C-terminus end, where X represents any 
amino acid and L stands for ligand (Murphy 2002). According to the 2003 IUIS/WHO 
classification, the chemokines are designated corresponding to their subfamily as CCL1-28, 
CXCL1-17, XCL1-2 and CX3CL1. 
Chemokines mediate their biological effects through G-protein-coupled receptors (GPCRs), 
which belong to the group of seven-transmembrane domain receptors (Holmes et al. 1991). 
These chemokine receptors have a chain length of 340 to 370 amino acids. The N-terminus 
lies outside the cell membrane, three extracellular and three intracellular loops span the cell 
membrane and the C-terminus is located in the cytosol (Singh et al. 2007). Most chemokine 
receptors bind several chemokines of the same subfamily with different affinities. Some 
chemokine receptors such as CXCR4 interact with its ligand, in this case CXCL12, with high 
affinity (Bleul et al. 1996b). 
The main function of chemokines and their corresponding receptors is to induce chemotaxis 
of blood cells, i.e. initiate the targeted migration of cells along a gradient to the site of the 
highest chemokine concentration (Zlotnik and yoshie 2000, Schier 2003). Chemokines are 
also known to be crucial regulators in the migration of other cell types. O´Harye et al. showed 
that chemokines play a key role in the progression of tumour development and also as an 
important chemoattractant aid in forming the tumour’s microenvironment. Moreover, 
chemokines ensure survival and proliferation of metastasised cells (O´Harye et al. 2008). 
Furthermore, chemokines such as CXCL12 are essential for embryogenesis, organogenesis, 
haematopoiesis (Nagasawa et al. 1996, Ma et al. 1998, Zou et al. 1998, Bagri et al. 2002, 
Doitsidou et al. 2002), organ-specific metastasis (Müller et al. 2001) and (tumour) 
angiogenesis (Liang et al. 2007). The major focus of the present study is the chemokine 
receptor CXCR4 and its ligand CXCL12. 
1.3.2.1 CXCL12 and its receptor CXCR4 
CXCL12 (also known as SDF-1, stromal cell-derived factor-1) belongs to the CXC 
chemokine subfamily and was originally isolated from a stromal cell line of murine bone 
marrow (Tashiro et al. 1993). The gene encoding an 8 kDa protein with 72 amino acids is 
located on chromosome 10. CXCL12 is the natural ligand for the two GPCRs; CXCR4 (Bleul 





all organs and tissues (Shirozu et al. 1995, Yu et al. 2006), including endothelial cells 
(Nagasawa et al. 1994, Imai et al. 1999, Ponomaryov et al. 2000, Ceradini et al. 2004), 
fibroblasts/osteoblasts, heart (Askari et al. 2003), brain (Zou et al. 1998) and kidney 
(Schrader et al. 2002). However, the highest concentration of CXCL12 is found in the bone 
marrow (Ponomaryov et al. 2000). 
The main biological function of CXCL12 is the ability to induce processes, such as 
chemotaxis, adhesion, cell motility, and the secretion of MMPs (matrix metalloproteinases) 
and angiogenic factors (Kucia et al. 2004). Thus endothelial cells can be stimulated directly 
by CXCL12 to migrate and promote angiogenesis (Salcedo and Oppenheim 2003). 
The receptor CXCR4 consists of 352 amino acids (40 kDa) and is highly conserved. The gene 
encoding CXCR4 is located on chromosome 2 (Horuk 2001). CXCR4 was discovered and 
cloned in leukocytes (Loetscher et al. 1994). In 1996 its role as cofactor for the absorption 
and penetration of HIV-1 (human immunodeficiency virus-1) was reported (Feng et al. 1996). 
In the same year it was found that it binds CXCL12 with high affinity, after which it was 
named CXCR4 (Bleul et al. 1996b). Many studies have shown that CXCR4 is expressed in 
almost all tissues and cell types as opposed to other chemokine receptors. In addition to cells 
of the haematopoietic system (Wang et al. 1998, Kowalska et al. 1999), CXCR4 is expressed 
in endothelial cells (Gupta et al. 1998, Tachibana et al. 1998, Volin et al. 1998, Murdoch et 
al. 1999a), epithelial cells (Murdoch et al. 1999b) and, in particular, in CD34
+
 progenitor 
cells (Aiuti et al. 1997) and also in tumour cells (Müller et al. 2001, Libura et al. 2002, Kucia 
et al. 2004, Hartmann et al. 2005). Even cells of the central nervous system and the 
gastrointestinal tract are positive for CXCR4 (Zou et al. 1998, Nagasawa 2001). 
CXCR4 is responsible for a wide range of effects in a variety of cell types. This includes 
CXCL12-directed chemotaxis of monocytes, T-lymphocytes and haematopoietic stem cells 
(Bleul et al. 1996b, Aiuti et al. 1997, Kim and Broxmeyer 1998). In addition, CXCR4 plays a 
role in the pathogenesis of a number of diseases, such as arteriosclerosis and multiple 
sclerosis (Zernecke et al. 2005, Calderon et al. 2006). In breast cancers expressing CXCR4, 
tumour progression and metastasis are much faster than in CXCR4-negative tumours (Müller 
et al. 2001). Furthermore, it was shown that CXCR4 is involved in the invasion and 
angiogenesis of pancreatic cancer (Matsuo et al. 2009).  
CXCL12 binding to CXCR4 leads to a conformational change of the chemokine receptor that 





which assists in the exchange of GDP (guanosine diphosphate) for GTP (guanosine 
triphosphate) on the Gα subunit (Percherancier 2005). These events cause the activation of 
various signalling pathways (MEK1/2, MAPK, AKT), which eventually lead to increased IL-
6 and VEGF secretion and induction of chemotactic migration along a CXCL12 gradient in 
various cell types (Kucia 2005). 
CXCR4 has been reported to be overexpressed in various types of cancers, including breast 
cancer (Müller et al. 2001), ovarian (Jiang et al. 2006), colorectal (Kim et al. 2005), and oral 
cancer (Almofti et al. 2004, Ishikawa et al. 2006). In colorectal cancer, the occurrence of 
lymphatic or distant metastases was significantly associated with CXCR4 expression 
(Ottaiano et al. 2006, Yoshitake et al. 2008). In OSCC patients, a statistically significant 
connection between CXCR4 expression and lymph node metastasis was reported, while 
treatment with CXCL12 increased the invasiveness of CXCR4-positive OSCC cells (Ishikawa 
et al. 2006). However, Zlotnik et al. noted that a CXCL12/CXCR4 gradient is correlated with 
distant metastatic spread rather than with lymph node metastasis (Zlotnik 2004).  
There have been attempts to inhibit CXCR4 as a therapeutic target since the significance of 
this receptor in diverse disease entities was discovered. AMD3100 (Plerixafor
®
) is a bicyclam 
molecule (Figure 1.6), which was originally developed as a specific antagonist of CXCR4 for 
the treatment of HIV infection by blocking the entry of HIV into target cells (CD4
+
 T-cells).  
 
 
Figure 1.6: Chemical structure of the AMD3100 (Plerixafor). AMD3100 is a metal-chelating, 
bicyclic, reversible CXCR4 inhibitor that binds to CXCR4 and leads to allosteric modulation and 






AMD3100 inhibits the binding of CXCL12 to CXCR4 by activating a G-protein coupled with 
CXCR4 and thus acts as a partial CXCR4 agonist in vitro (Zhang et al. 2002). It binds with 
high affinity to CXCR4, independent of the cell type expressing CXCR4, but does not interact 
with other chemokine receptors (Hatse et al. 2002). In addition, AMD3100 prevents 
intracellular calcium signalling and chemotactic response caused by CXCL12 in various cell 
types (Schols et al. 1997, Donzella et al. 1998). Moreover, several studies have shown that 
AMD3100 decreased metastasis formation in mice (Smith et al. 2004) as well as the 
recurrence of glioblastoma in a mouse model after RT (Kioi et al. 2010). Uchida et al. also 
showed that subcutaneous administration of AMD3100 inhibited the formation of lymph node 
metastases after an HNSCC cell line expressing CXCR4 was inoculated into the masseter 
muscle of nude mice (Uchida et al. 2010).  




1.4 Aims of the present study 
1. High-grade acute organ toxicity (HGAOT) as a potent prognostic marker for HNSCC 
patients and p16
INK4A
 overexpression as a known surrogate marker for HPV-positive HNSCC 
patients have been investigated. However, no studies have been performed to analyse both of 
them in combination. The aim of this part of the study was to analyse their combined impact 
on patient survival. 
 To analyse the prevalence of HPV infection by screening the HPV DNA status in 
tumour biopsies from 233 HNSCC patients treated between 1992 and 2011  
 To analyse the HPV subtype by nested-PCR-product sequencing  
 To analyse the expression of p16INK4A in the 233 pre-treatment HNSCC biopsies by 
means of IHC staining in correlation with clinical outcomes and survival data 
 To analyse the impact of both HGAOT and HGAHT during/after R(C)T and p16INK4A 
expression on the survival data of HNSCC patients 
2. Some of the studies investigating CXCR4- and CXCL12-dependent tumour development 
and metastasis in lymph node and/or distant organs comprise only a small number of patients 
in the HNSCC collective. The second aim of this work was therefore to gain more reliable 
results by further investigating the impact of primary tumour levels of CXCL12 and CXCR4 
expression in 233 pre-treatment HNSCC biopsies by means of immunohistochemistry 
staining.  
 
 To analyse the impact of CXCL12 and CXCR4 expression on pre-treatment patient’ 
data 
 To analyse the impact of CXCL12 and CXCR4 expression on patient survival 
 To analyse the impact of CXCL12 and CXCR4 expression on regional lymph node or 
distant metastasis 




3. Although migration of primary tumour cells is one of the most important components in the 
formation of metastases, little is known about the chemotactic effects of CXCL12-induced 
HNSCC cell migration under irradiated condition. Hence the aim of this part of the study was 
to analyse this effect in HNSCC cell lines with different CXCL12 and CXCR4 expression 
patterns. 
 To investigate, in three HNSCC and two control cell lines, 
 the expression profiles of CXCL12 and CXCR4 at the mRNA and protein 
levels  
 the radiosensitivity of cells using a colony-forming assay, including treatment 
with CXCL12 and AMD3100 
 the metabolic activity of cells by means of CellTiter®-Blue cell viability assay 
after treatment with CXCL12, AMD3100 and radiation 
 To investigate the impact of CXCL12 on the migration of HNSCC and control cell 
lines by means of Boyden -chamber migration assay  
 To investigate the influence of different doses of radiation on cell migratory 
behaviour in cells with different patterns of CXCL12 and CXCR4 expression 
 To investigate the migration-inhibiting effect of AMD3100 in CXCR4-
expressing  HNSCC cell lines  
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2. Materials and methods 
2.1 Materials  
2.1.1 Laboratory equipment 
Table 2.1: List of laboratory equipment used during the work  
Name of product Name of the company 
(city or country of origin) 
Clean bench 
 




Liebherr (Biberach, Germany) 
Freezer (-20°C) 
Deep freezer (-80°C) Sanyo (Osaka, Japan) 
Light microscope  Carl Zeiss (Jena, Germany) 
Light microscope with camera Olympus BX40 (Japan) 
Pipethelper "Pipetboy comfort" Integra Biosciences (Fernwald, Germany) 
Wallec 1420 VICTOR 
TM 
plate reader PerKinElmer (Turku, Finland) 
Cytospin 4 cytocentrifuge Thermo Scientific (Rockford, USA) 
Vortex shaker Heidolph (Schwabach, Germany) 
Luminometer Tecan (Crailsheim, Germany) 
Ice-machine Ziega (Isernhagen, Germany) 
Ultrasonic homogenizer Bandelin (Berlin, Germany) 
Small cup centrifuge  
Eppendorf AG (Hamburg, Germany) 
Thermomixer comfort 
Unsterile clean bench Norddeuche Laborbau (Kaltenkirschen, Germany) 
Western Blot migration set Mini-
PROTEAN Tetra System  
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2.1.2 Experimental and detection kits 
Table 2.2: List of experimental and detection kits used during the work  
Name of product Name of the company 
 (city or country of origin) 
CellTiter-Blue®Cell Viability Assay Promega (Madison, USA) 
Bradford colorimetric protein assay Bio-Rad (Hercules, USA) 
Electrophoresis transfer pack Trans-Blot 
Turbo 
Bio-Rad (Hercules, USA) 
Electrophoresis power supply Power Pac 
300 
 
Bio-Rad (Hercules, USA) 






 Transfer Gel 
CoolCell ® cell freezing container Biocision (Burusapat et al.) 
Rotary shaker Zeipel (Bovenden-Lenglern, Germany) 
Balance Sartorius GmbH (Göttingen, Germany) 
microtome Microm HM400(Walldorf, Germany) 
Automated slide stainer Ventana BenchMark (Tucson, USA) 
NanoDrop ND-2000 spectrophotometer Thermoscientific (Pittsburgh, USA) 
Automated capillary electrophoresis 
QIAxcel 
Qiagen (Hilden, Germany) 
Labcycler  Sensoquest (Göttingen, Germany) 
Real-time PCR machine HT7900, Applied Biosystems (Foster City, 
California, USA) 
Spectrophotometer LabelGuard cuvette, Implen (Munich, Germany) 
Microcentrifuge for PCR tubes 
Star Lab (Korea) 
Air Clean 600 PCR workstation  
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Western Blot immunodetection 
WesternBreez® Chromogenic kit Invitrogen (San Diego, USA) 
ZytoChem-Plus HRP Polymer-Kit Zytomed Systems GmbH (Berlin, Germany) 
IHC- detection Kit Dako K5005 (Denmark) 
QIAamp® DNA Mini Kit (250) Qiagen (Hilden, Germany) 
SuperHot Master Mix (2x) Bioron (Ludwigshafen, Germany) 
Wizard® SV Gel and PCR Clean-Up System Promega (Madison, USA) 
Transwell chamber assay Greiner Bio-one (Frickenhausen, Germany) 
Diff-Quick kit Medion Diagnostics (Düdingen, Switzerland) 
RNeasy mini kit  Qiagen (Hilden, Germany) 
Super-Script II reverse transcriptase Invitrogen (Carlsbad, California, USA) 
Recombinant RNase inhibitor 
USB (Cleveland, Ohio, USA) 
HotStart-IT SYBR Green qPCR-Master mix 
2.1.3 Buffers and media for cell culture 
Table 2.3: List of used buffers and media for cell culture during  the work 
Name of product Name of the company (city or country of 
origin) 
DMEM (Dulbecco’s Minimum Essential 
Medium) 
Biochrom (Berlin, Germany) 
RPMI 1640 medium Biowest (Nuaille, France) 
FCS (fetal calf serum) Biochrom (Berlin, Germany) 
Ampicillin Ratiopharm (Ulm, Germany) 
PBS Biochrom (Berlin, Germany) 
Trypsin Biochrom (Berlin, Germany) 
Running buffer for SDS-PAGE SERVA (Heidelberg, Germany) 
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2.1.4 Consumption materials 
Table 2.4: List of consumption materials used during the work  
Name of product Name of the company (city or country of 
origin) 
Freezing resistant plastic vials  
Greiner Bio-One (Frickenhausen, Germany) Plastic sterile 15 and 50 ml tubes 
Sterile/unsterile 10 and 25 pipettes 
Sterile 50 and 200 ml flasks 
Neubauer counting chamber  Paul Marienfeld (Lauda-Königshofen, Germany) 
Pipette  Eppendorf AG (Hamburg, Germany) 
Sterile pipette tips  
Sterile 96-well black plates with clear bottom  Costar (New York, USA) 
Glass microscopic slide (superfrost plus) Thermo Scientific (Braunschweig, Germany) 
Glass microscopic slide (cut edges frosted end) Thermo Scientific (Braunschweig, Germany) 
Glass coverslips Thermo Scientific (Braunschweig, Germany) 
Sterile cell scraper  Sarstedt (Newton, USA) 
Sterile insulin injections  Braun (Bad Arolsen, Germany) 
Sterile PCR tubes  Sarstedt (Germany)  
96-well multiply PCR plate Sarstedt (Germany) 




Table 2.5: List of antibodies used during the work  
Name of product Methods Name of the company  
(city or country of origin) 
Anti-P53 IHC monoclonal mouse anti-human p53 protein 




IHC, ICC monoclonal mouse IgG1; Clone No.: 79018 
R&D system (Abingdon, UK) 
Anti-CXCR4 IHC, WB Rabbit monoclonal antibody; Ab 2074 
Abcam (Cambridge, UK) 
Anti-p16 
INK4A
 IHC monoclonal mouse IgG2a ; Clone: JC8  
SC-56330 
Santa Cruz Biotechnology (Texas, USA) 
Anti-actin WB Monoclonal Anti-ß-Actin antibody produced in 
mouse ; Lot Nr: 121M4846 
Sigma-Aldrich (Missouri, USA) 
2.1.6 Software and online tools 
Table 2.6: List of software and online tools used during the work  
Software Source 
Microsoft Office Excel Microsoft (Albuquerque) 
Kaleidergraph® Version 4.1 Synergy Software (Reading, USA) 
Chromas Lite version 2.1.1. Technelysium (Australia) 
ImageJ National Institutes of Health (Bethesda, MD) 
STATISTICA 9 StatSoft (Tulsa, USA) 
Basic Local Alignment Search Tool 
(Balermpas et al.) 
NCBI (Bethesda, USA) 
http://www.ncbi.nlm.nih.gov 




2.2 Methods for In vivo analysing HNSCC biopsies 
2.2.1 Clinical specimens from HNSCC patients 
A total of 233 patients with head and neck cancers were evaluated in this study. The 
histological diagnosis was SCC in all cases. All 233 tumour samples included in the study 
were fixed in formalin and embedded in paraffin (FFPE). The patients had been diagnosed 
with primary inoperable HNSCC without distant metastases. Tissue samples had been taken 
between 1992 and 2011 in the Department of Otorhinolaryngology of University Medical 
Centre Göttingen. The specimens and clinicopathological data were used with the approval of 
the local Ethics Committee. The clinical data of 183 patients have already been published 
(Wolff et al. 2010a), and these data were updated for this investigation. The 
clinicopathological data provide general patient information such as gender, age, site of 
primary tumour, diagnosis, histopathology, treatment, side-effects of therapy and follow‐up 
data such as date and cause of death (Table 3.1). 
2.2.1.1 HNSCC patient treatment and analysis of toxicity 
The patients suffering from head and neck cancer evaluated in the current study were treated 
in accordance with respective clinical and technical standards. In the period from 06/1994 to 
11/1999, 138 patients underwent a normofractionated definite (primary) RT (2 Gy/day, 5 
times/week) as parallel-opposed lateral portals. In the period from 12/1999 to 10/2008, 45 
patients were given a normofractionated (2 Gy/day, 5 times/week) 3-D conformal external-
beam RT with a total dose of 70 Gy in each case (Wolff et al. 2011b). Integrated intensity-
modulated radiotherapy (IMRT) with single fractions of 2.2 Gy to the primary tumour and the 
involved lymph nodes up to a total of 66 Gy and single fractions of 1.8 Gy to the drainage 
sites on both sides of the neck up to a total of 54 Gy daily (5 times/week) (Tehrany et al. 
2015) was applied to 50 patients, from 11/2008 to 11/2011. In addition to the RT a 
supplementary concomitant CT consisting of 5-fluorouracil plus mitomycin C or of cisplatin 
alone was administered to 171 patients. 
Toxicity was monitored in the Department of Radiotherapy and Radiation Oncology of 
University Medical Centre Göttingen, weekly during treatment and every second week 




following the end of therapy until the disappearance of acute toxicity. Subsequently, chronic 
toxicity was monitored at least yearly. Toxicity was classified according to the CTC score for 
acute effects (Cox et al. 1995, Trotti et al. 2000, Trotti et al. 2003) and according to the “Late 
Effects on Normal Tissue” scoring system for chronic toxicity (Rubin et al. 1995, Hendry et 
al. 2006). Before data analysis, acute organ toxicity or acute hematotoxicity grade 3 or higher 
was chosen as the cut-off value for high-grade acute toxicity because patients with toxicity 
grade 3 or higher have a strongly impaired quality of life. For further analysis, acute toxicity 
was scored as high-grade acute organ toxicity (HGAOT) or high-grade acute hematotoxicity 
(HGAHT) if one or more items were scored as CTC grade 3 or higher. The acute organ 
toxicity items in this study were mucositis, skin reaction, dysphagia and nausea, while the 
acute hematotoxicity was observed as anaemia, leukopenia and thrombocytopenia. 
2.2.2 Immunohistochemistry (IHC) 
Immunohistochemical staining of CXCR4, CXCL12, p16
INK4A
 and p53 was performed on 2 
µm slices of FFPE tissue samples from 233 pre-treatment HNSCC biopsies. Tissue sections 
were deparaffinized with three washes in xylene for five minutes each and rehydrated with 
distilled water through an ethanol series. Tissue antigens for CXCL12 and p16
INK4A
 were 
retrieved in boiled citrate buffer (2.1 g/L citric acid, pH 6.0) with incubation for 40 minutes. 
This step was not necessary for CXCR4 and p53. The tissue sections were then incubated in a 
blocking solution (2% BSA) to eliminate non-specific binding. The specimens were then 
incubated for two hours at room temperature with their specific primary antibodies (see listed 
antibodies in Table 2.5). Afterwards, the specimens were incubated for 20 minutes at room 
temperature with a biotinylated secondary antibody (Dako K5005). After extensive rinsing, 
they were developed using the streptavidin-biotin-peroxidase complex technique (Dako 
K5005). Negative control (absence of primary antibodies) and positive controls (FFPE human 
cell lines of known CXCR4, CXCL12 and p16
INK4A
 reactivity) were included for each 
staining. The quality of samples was confirmed by immunohistochemical staining for p53. 
2.2.2.1 Scoring of the immunohistochemistry staining 
The sections were examined microscopically by a pathologist and me without knowledge of 
the clinicopathologic data. The expression of targeted proteins was evaluated using a visual 
grading system based on the percentage of positive stained cells and the intensity of staining 




(graded on a scale of 0 to 3; 0: no staining; 1: weak staining; 2: moderate staining; 3: strong 
staining). The expression of targeted proteins was scored positive when more than 5% cells 
(cut-off) stained positively (Fregonesi et al. 2003). In addition, expression of p16
INK4A
 was 
separately graded as described: negative (0-5% of nuclei and cytoplasm positive), focal or 
patchy (5-30% of nuclei and cytoplasm with weak and scattered positivity), and diffuse 
(>30% of labelled cells with strong positivity). A weighted score was assumed to each case by 
multiplying the percentage of stained cells by the staining intensity scores (Xia et al. 2011). 
2.2.3 HPV DNA analysis 
2.2.3.1 HPV DNA extraction  
The 233 FFPE tumour biopsies were analysed for the existence of HPV DNA. Seven 5µm 
scrolls were cut from each of the 233 FFPE biopsies. In the first step, these samples were 
deparaffinised following the existing protocol in the Department of Pathology of University 
Medical Centre Göttingen and the DNA was then extracted from the samples using the 
Nucleic Acid-Isolation Kit (QIAamp DNA Mini Kit) according to the manufacture´s 
instruction. 
2.2.3.2 Sample DNA quality assessment 
The concentration of eluted DNA was measured with a NanoDrop ND-2000 
Spectrophotometer. The purity of the DNA samples was determined by the ratio 
A260nm/A280nm. The A260/A280 ratio provided an estimate of the purity of the nucleic acid, with 
a value of 1.8-2.0 representing pure preparation (Sambrook et al. 1989). The samples were 
stored for further analysis at -20°C. 
The quality of the DNA was confirmed by using 5 µl aliquots of each DNA sample for PCR 
analysis of the human beta-globin gene with the PC04 and GH20 primers (see listed used 
primers in Table 2.7) using the same program described for primary PCR of nested-PCR (see 
Chapter 2.2.2.4). The amplified gene fragment was 268 bp in size and visualised on the 
automated capillary electrophoresis QIAxcel system. The primer sequences were synthesized 
by Eurofins MWG, Ebersberg, Germany (http://eurofinsgenomics.com).  




2.2.3.3 PCR analysis 
The polymerase chain reaction (PCR) method allows the amplification of specific DNA 
sequences from small amounts of DNA-containing material. In repetitive cycles of DNA 
denaturation, primer annealing and elongation, the DNA sequences are amplified. The 
reaction is catalysed by a thermostable DNA polymerase and uses dNTPs and several or two 
oligonucleotide primers for primary and nested-PCR, respectively. To increase the sensitivity 
and/or specificity of PCR, nested-PCR was used in this study. Nested-PCR consists of two-
PCR steps in sequence. Two different sets of PCR primers are used to amplify the same target 
sequence. The first primer mix (consist of 18 primer sequences) amplifies the target sequence 
as seen in any PCR experiment and the second pair of primers (nested-primers) bind within 
the first PCR product and produce a second PCR product that will be shorter than the first 
one. The logic behind this strategy is that nested-PCR offers an increase in sensitivity over the 
primary PCR.  
Table 2.7: List of used primers for PCR assays  
Primer designation Primer sequences 
PGMY 09/11 
PGMY 11-A 5´- GCA CAG GGA CAT AAC AAT GG -3´ 
PGMY 11-B 5´- GCG CAG GGC CAC AAT AAT GG -3´ 
PGMY 11-C 5´- GCA CAG GGA CAT AAT AAT GG -3´ 
PGMY 11-D 5´- GCC CAG GGC CAC AAC AAT GG -3´ 
PGMY 11-E 5´- GCT CAG GGT TTA AAC AAT GG -3´ 
PGMY 09-F 5´- CGT CCC AAA GGA AAC TGA TC -3´ 
PGMY 09-G 5´- CGA CCT AAA GGA AAC TGA TC -3´ 
PGMY 09-H 5´- CGT CCA AAA GGA AAC TGA TC -3´ 
PGMY 09-I 5´- G CCA AGG GGA AAC TGA TC -3´ 
PGMY09-J 5´- CGT CCC AAA GGA TAC TGA TC -3´ 
PGMY 09-K 5´- CGT CCA AGG GGA TAC TGA TC -3´ 
PGMY 09-L  5´- CGA CCT AAA GGG AAT TGA TC -3´ 





To screen the presence of HPV in the samples, a nested-PCR consisting of the PGMY 09/11 
primer mix (for the primary PCR) (Gravitt et al. 2000) and the GP5+/6+ primer set (for the 
secondary PCR) (de Roda Husman et al. 1995, Gravitt et al. 2000) targeting the L1-ORF of 
the HPV genome was used. The list of the primers used for nested-PCR and also β-globin 
PCR are summarised in Table 2.7.  
Primary PCR  
Briefly, the final 25 µl PCR mixture containing 5 µl DNA and 12.5 µl of master mix 
(BIORON) was amplified with 2 µl of the PGMY 09/11 primer mix (10 pmol each). 
Amplification was performed using the following cycling conditions: incubation at 94°C for 
three minutes followed by 40 cycles of one minute denaturation at 94°C, one minute 
annealing at 54°C, and one minute elongation at 72°C. The last cycle was followed by a final 
extension for five minutes at 72°C and then storage at 4°C. 
PGMY 09-M 5´- CGA CCT AGT GGA AAT TGA TC -3´ 
PGMY 09-N 5´- CGA CCA AGG GGA TAT TGA TC -3´ 
PGMY 09-P 5´- G CCC AAC GGA AAC TGA TC -3´ 
PGMY 09-Q 5´- CGA CCC AAG GGA AAC TGG TC -3´ 
PGMY 09-R 5´- CGT CCT AAA GGA AAC TGG TC -3´ 
HMB01 5´- GCG ACC CAA TGC AAA TTG GT -3´ 
GP5+/6+ 
Gp5+ 5´- TTTGTTACTGTGGTAGATACTAC -3´ 
GP6+ 5´- GAAAAATAAACTGTAAATCATATTC -3´ 
ß-globin 
PC04 5´- CAACTTCATCCACGTTCACC -3´ 
GH20 5´- GAAGAGCCAAGGACAGGTAC -3´ 




Secondary PCR (nested-PCR)  
The end product of the first PCR was diluted 1:10, and one microliter of this sample and 7.5 
µl of the master mix (BIORON) were used for the nested-PCR using 1.2 µl GP5+/GP6+ 
primers in a 15 µl PCR mixture. The GP5+/GP6+ primers consisted of a fixed nucleotide 
sequence for each of the 18 primers of the first PCR and detected a wide range of HPV types 
by using a lower annealing temperature during PCR. The PCR cycling conditions were as 
follow: denaturing step at 95°C for five minutes, followed by 30 cycles of 95°C for one 
minute, then 40°C for two minutes and 72°C for one and half minutes. This last cycle was 
followed by a final extension period of ten minutes at 72°C. 
Positive (low-risk HPV-6 subtype) and negative (PCR-water (BIORON) instead of extracted 
DNA) controls were included during amplification. The amplified gene fragments of the 
primary and secondary PCRs were 450 bp and 140 bp, respectively, and were visualised on 
the automated capillary electrophoresis QIAxcel system. 
To avoid any contamination, the PCR mixture without DNA was pipetted in a room with an 
“air clean PCR workstation”. DNA was extracted under sterile conditions in a separate 
laboratory. DNA was added to the PCR reaction mixture in a third laboratory room.  
2.2.3.5 Sequencing and HPV subtyping 
The PCR products from any samples positive for the primary and/or secondary PCR were 
purified using the Wizard® SV Gel and PCR Clean-Up System. The purified PCR products 
were then subjected to automated DNA sequencing based on Sanger sequencing method 
(Sequence Laboratories Göttingen GmbH, Germany, www.seqlab.de). The purified PCR 
product used for sequencing consisted of six microliters of the eluted PCR product and one 
microliter GP5+ primer.  
Sequencing results were downloaded from the SeqLab website, and analysed using “Chromas 
Lite” software. Analysed sequences were compared to available databases, using the Basic 
Local Alignment Search Tool (Balermpas et al.) to determine approximate phylogenetic 
affiliations (NCBI, www.ncbi.nlm.nih.gov). 




2.2.4 Statistical analysis 
Fisher’s exact test was used to test differences between groups on categorical variables. The 
patient survival times were calculated from the day of the histological diagnosis to death for 
any reasons (OS), to local recurrence (local recurrence-free survival (LRFS)) or to the end of 
study. Kaplan-Meier analysis was used to estimate OS, LRFS, disease-free survival (DFS), 
loco-regional control rates (LRC) as the absence of local and/or regional recurrence or 
progression, and distant metastasis-free survival (DMFS).  
Cox proportional hazards regression was used to analyse the impact of HPV infection, 
p16
INK4A
 expression and HGOAT on OS. With p16
INK4A
 and HGAOT a multivariate Cox 
regression versus OS was computed including an interaction term. The impact of CXCR4 and 
CXCL12 expression on patient survival was analysed by univariate Cox proportional hazards 
regressions. In addition, to test whether the association between marker expression and 
survival was independent of other possible prognostic factors or factors that might influence 
treatment outcome and which could bias the univariate analysis, an additional multivariate 
analysis (multivariate Cox regression) was performed.  
For the statistical tests the significance level was set as α = 5%. Statistical analyses were 














2.3 Methods for In vitro analysing HNSCC and control cell lines 
2.3.1 Cell cultures 
Three human HNSCC tumour cell lines and two control human cell lines were used for the in 
vitro experiments (see below). The cell lines were taken from stocks that were preserved in 
liquid nitrogen in the Department of Radiotherapy and Radiation Oncology at the University 
Medical Centre Göttingen. 
2.3.1.1 Cell lines 
Tumour cell lines 
ZMK-1 cell line 
This cell line is a poorly differentiated (grade 2) SCC of an oropharyngeal tumour from a 47-
year-old male patient obtained during tumour resection performed in 1996 by the Department 
of Oral and Maxillofacial surgery, University Medical Centre Göttingen. Cells from this 
tumour were isolated and cultivated in the Department of Radiotherapy and Radiation 
Oncology at the University Medical Centre Göttingen (Rave-Frank et al. 1996).  
FaDu cell line 
FaDu-cells are human epithelial cells that were isolated in 1968 from a SCC of the 
hypopharynx of a 56-year-old male Hindu patient (Rangans 1972). The cells were obtained 
from the American Type Culture Collection (ATCC). 
GR-145 cell line 
This cell line is a moderately differentiated (grade 2) SCC of an oropharyngeal tumour from a 
48-year-old male patient obtained during tumour resection performed in 1998 by the 
Department of Otorhinolaryngology at the University Medical Centre Göttingen. Cells from 
this tumour were isolated and cultivated in the Department of Radiotherapy and Radiation 
Oncology at the University Medical Centre Göttingen. 




Control cell lines 
HaCat cell line 
This spontaneously transformed epithelial cell line is an aneuploid, but highly differentiated, 
immortalized human keratinocyte cell line, which was gained from a histologically normal 
skin specimen. This skin specimen was obtained from a distant peripheral tissue of a 
malignant melanoma acquired in 1988 from a 62-year old male patient (Boukamp et al. 
1988). This cell line was supplied by Cell Lines Service (CLS, www.cell-lines-service.de).  
DF-19 cell line 
Primary fibroblasts were obtained from a skin spindle taken from a healthy 30-year-old male. 
The cells were isolated and cultivated in 2003 in the Department of Radiotherapy and 
Radiation Oncology at the University Medical Centre Göttingen. 
2.3.1.2 Culture conditions and media 
To prevent contamination of the cell cultures with bacteria or fungi, all used materials such as 
Eppendorf reaction tubes and pipette tips were autoclaved for 15 minutes at 121°C. Devices 
not autoclaved were regularly cleaned with 70% ethanol. All solutions, i.e. all growth media, 
cell culture additives and other reagents, were supplied sterile by the manufacturers and were 
only opened and used under the sterile hood. 
The cell lines were cultured in sterile culture flasks with two different capacities, 50 or 250 ml 
at 37°C and in an atmosphere containing 5% CO2. A volume of cell medium of 10 ml for the 
50 ml flasks and 20 ml for the 250 ml flasks was sufficient to cover the cells growing 
adherently in a monolayer. Depending on the cell line, every three to five days the cell 
medium was changed. After reaching a confluency of 80 to 90% cells were dissociated by 
trypsinisation, and were subcultured and reseeded in new culture flasks. The compositions 
and contents of each cell line-related medium are itemized in the following Table 2.8.  
Reagents and media were stored at 4°C. Fetal calf serum (FCS), trypsin and antibiotics were 
kept at -20°C for long term storage. All reagents and media were warmed slowly to 37 °C 
before use. 




Table 2.8: Culture mediums used for the cell lines  
2.3.1.3 Passage of adherent cell lines (subculture) 
The cell cultures were passaged by trypsinisation when required. The culture medium was 
drained from the flasks and residual medium was removed by rinsing with 2-3 ml of 
Phosphate Buffered Saline (PBS) without calcium and magnesium. The cell layer was slowly 
covered with 1-2 ml trypsin-EDTA solution (0.5 % trypsin; 0.2 % EDTA in PBS), and the 
flask was returned to the incubator for 5 to 10 minutes. The HaCat cells were more strongly 
attached to the bottom of the culture flask and required a second step in dissociation. The 
HaCat cells were washed additionally with 1 ml EDTA solution after the PBS wash. One ml 
of trypsin-EDTA solution was then added and incubated as described above. At the end of the 
incubation time the flasks were removed and shaken gently by hand to dislodge the cells. 
The flasks were inspected under the microscope to determine whether all cells had been 
detached from the flask bottom. The cells were then resuspended in fresh growth medium. 
2.3.1.4 Counting cells with the Neubauer counting chamber 
A Neubauer chamber is a four millimetres thick, 30 by 70 mm crystal slide with a counting 
grid. There are single or double chamber slides. Only double chamber slides with separate 
counting areas were used in this study; the upper and the lower chamber.  
A glass cover slip was placed over the grid of the chambers, and ten microlitre of cell 
suspension was pipetted into the chambers. Once both chambers were filled, the slide was 
placed under the light microscope. The number of viable cells in each of the 25 small squares 




DMEM and RPMI 1640 in ratio 1:1 including 10 % inactivated FCS and 1 ml 




DMEM including 10 % inactivated FCS and 1 ml Ampicillin (0.5 g/10 ml) 
 




of the central square is counted in both chambers. The average number of cells is calculated 
and multiplied 1 x 10
4
 to give the number of cells in one millilitre of our cell suspension.  
2.3.1.5 Cryopreservation and thawing of cells 
Cryopreservation  
Cryopreservation is the best method to store mammalian cells. Cryoprotectants are added to 
the cell suspension to prevent the formation of Intra- and extracellular ice crystal that would 
cause cell death. Dimethyl sulphoxide (DMSO) is the standard cryoprotectant. Cultures that 
had reached 80 to 90% confluency were harvested by trypsinisation. The cell suspension was 
centrifuged at 1200 rpm for ten minutes, and the cell pellet was resuspended in freezing 
medium (culture medium containing 9% DMSO). Two millilitre aliquots of cell suspension 
containing 1 × 10
6
 viable cells per ml were put into 2 ml plastic cryovials. These were frozen 
in a CoolCell
®
 container at -80°C for four hours before transferring them to long-term archive 
storage at -150°C. 
Thawing of frozen cells 
Frozen cell vials were thawed in a 37°C water bath, until a liquid film had formed and the 
remaining solid block could be transferred to a flask containing ten millilitres of the 
appropriate medium, and the cells were allowed to attach. To remove residual DMSO, the 














2.3.2 Real-time PCR 
The cells (1 x 10
6 
cells/ml) were washed in PBS before storing them in lysis buffer at -80°C. 
To extract and isolate RNA from our used cells for real-time PCR, RNeasy mini kit (Qiagen) 
was used according to the manufacturer’s instructions. The RNA amounts were then 
measured by a spectrophotometric method. Super-Script II reverse transcriptase was used to 
carry out reverse transcription to complementary DNA with 1 μg total RNA for one hour, 
under inhibition of RNase by adding 20 units recombinant RNase inhibitor per each samples. 
In a real-time PCR machine, the quantification of transcript numbers of target and reference 
genes was determined relatively by using HotStart-IT SYBR Green qPCR-Master Mix (USB). 
The amplification condition of the PCR was composed of 40 to 50 cycles (dependent on 
expression level). The annealing step lasted 20 s accomplished at 60°C and the elongation 
step was performed for 40 s at 72°C for each primer pair (Wolff et al. 2011a).  
The primer sequences were synthesized by MWG, Ebersberg, Germany (primer sequences 
given in Table 2.9). Data were normalized to weighted mean expression of HPRT1 using as 
reference gene (Wolff et al. 2011a).  
 
Table 2.9: primer pairs used for the analysis of CXCL12 and CXCR4 transcript expression  
2.3.3 Western blot analysis 
2.3.3.1 Protein extraction 
All steps of protein extraction were performed at 4°C. For cell lysis, growth medium was 
removed and the cells were washed twice with 5 ml cold PBS to remove all residual medium. 
Gen Primer sequences 
 Forward primer Reverse primer 
CXCL12 5´- GGT CGT GGTCGTGCTGGT -3´ 5´-CGG GCT ACA ATC TGA AGG G -3´ 
CXCR4 5´-TAC ACC GAG GAA ATG GGC TCA -3´ 5´- AGA TGA TGG AGT AGA TGG TGG G-3´ 
HPRT1 5´-TGA CAC TGG CAA AAC AAT GCA -3´ 5´-GGT CCT TTT CAC CAG CAA GCT -3´ 




The cells were then scraped off the flask bottom with a cell scraper and resuspended in PBS. 
This suspension was centrifuged at 1200 rpm for eight minutes at 4°C. After the 
centrifugation, the PBS supernatant was removed. 
500 μl of lysis buffer (see the composition of the lysis buffer in Table 2.10) was added to the 
cell sediment and stirred carefully. Ultrasound was used to facilitate cell lysis and protein 
release with the following parameters: four times with duration of 0.9 seconds and 42 % 
intensity.  
Table 2.10: Composition of the lysis buffer  
Substrate Molecular weight (MW) Dilutions 
20 mM Tris HCl (pH=7.5) 157.60 0.0315 g/100 ml water 
150 mM NaCl 58.60 0.0876 g/100 ml water 
1 mM MgCl2 203.30 0.002 g/100 ml water 
1 mM CaCl2 147.02 0.0014 g/100 ml water 
1% NP-40 - 1 ml/100 ml water 
10% glycerol - 10 ml/100 ml water 
10 ml lyse buffer 
+ 1 pill of Mini, EDTA-free, protein inhibitor 
The cell-buffer suspension was incubated on ice for ten minutes in order to let the foam 
subside. A series of five to six passages through a fine insulin cannula was done manually to 
increase protein release. This step was repeated after ten minutes. After the final passage, the 
suspension from each tube was transferred into a nonsterile, 1.5 ml plastic cup and 
centrifuged at 6000 rpm for ten minutes at 4 °C.  
The lysate was transferred to a fresh 1.5 ml cup for Bradford assay and western blot. Lysates 
were kept on ice until use or at -80°C for long-term storage. 
2.3.3.2 Bradford assay 
Protein concentrations in the samples, were determined by Bradford assay (Bradford 1976). 
Bovine serum albumin (BSA) was used to prepare a standard curve (with 0 to 2 mg/ml protein 




concentration range). First a standard curve was prepared, by defining the standard 
absorbance values on the y-axis and their concentrations in mg/ml on the x-axis, in order to 
determine unknown protein concentrations. One millilitre Bradford solution (Bio-Rad) was 
added to each vial and mixed by inversion. The blank sample was 20 μl sterile water in one 
millilitre of Bradford solution. The absorbance of the prepared standard concentration 
samples were measured at 595 nm and the standard curve was drawn. For samples with 
unknown protein concentration, 20 μl of the samples was added to one millilitre Bradford 
solution and the absorbance was measured. The values were entered into the standard curve to 
obtain the protein concentration of the sample. 
The measurements were performed in duplicate to improve the accuracy of the determination. 
The results corresponded to the protein concentration in 20 µl of lysate. The amount of lysate 
required for loading the electrophoresis gel was calculated by dividing 20 µl of lysate volume 
by the concentration. In order to reach a final volume of 20 µl, we calculated the volume of 
sodium dodecyl sulphate (SDS) buffer that had to be added (see the SDS buffer consistence in 
Table 2.11). 
2.3.3.3 Gel electrophoresis  
Purified proteins were separated on precast 10-well polyacrylamide gels (TGX-gel). The gels 
were placed in the migration set that consisted of a tank, lid, and an electrode assembly. The 




Adequate volumes of the protein lysate and SDS buffer-mercaptoethanol solution (see Table 
2.11) were mixed together. These mixtures were centrifuged for a few seconds by rapid 
acceleration. Afterwards they were incubated for five minutes at 95 °C.  
Samples were loaded into wells of the TGX-gel and run against protein standards. The gel 
electrophoresis was performed at 200 V and 30 mA. Once migration was over, the proteins 








Table 2.11: SDS buffer consistence 
 
2.3.3.4 Western blotting 
After the proteins had been separated by electrophoresis, they were transferred by 
electroblotting to a nitrocellulose membrane. In electroblotting an electric current is used to 
propel the proteins from the gel onto the nitrocellulose membrane while maintaining their 
pattern. 
Electroblotting was done with the Trans-Blot Turbo
TM
 Transfer system following the 
manufacture’s instruction using a transfer time of three minutes. The protein-loaded 
membranes were then stained with the sodium salt of a diazo dye. The loading and transfer 
efficiency was analysed with this procedure. The dye was later washed out with water. 
Western blotting of the nitrocellulose membrane was performed after protein transfer. Prior to 
incubating the protein-loaded membranes with the primary antibody, the membrane-blocking 
step is crucial to avoid non-specific primary antibody binding in protein in free spaces. For 
this purpose a WesternBreez
®
 Chromogenic Western blot immunodetection kit was used. The 
membrane was blocked with blocking solution for 30 minutes on a rotatory shaker followed 
by two washes of five minutes with distilled water. 
Following this, the primary antibody was incubated on the membrane for one hour at room 
temperature or over-night at 4°C. For the present study, rabbit anti-CXCR4 monoclonal 
antibody (see Table 2.5) was used.  
Beta-actin, as a ubiquitous structural protein, was used to confirm equal loading of the protein 
lysates. Due to an almost identical molecular weight of the two targeted proteins (molecular 
weights of CXCR4 and β-actin proteins were approximately 40 and 42 kDa, respectively), 
western blotting was performed to detect each protein separately on two individual 
SDS buffer (pH= 7.4) 30 mM Tris-Base 
9 %  SDS 
15 % glycerine 
0.04 % bromphenol blue Na-salt 
10 %  2-mercaptoethanol 




membranes. For this purpose monoclonal mouse anti-β-actin antibody was applied as primary 
antibody (Table 2.5). The primary antibodies were diluted in five millilitres of blocking 
solution in order to obtain the dilutions recommended by the manufacturers. For anti-CXCR4 
a dilution of 1:500 and for anti-β-actin a dilution of 1:10 000 was used. 
An incubation time of one hour was kept. After the membranes had been washed three times 
for five minutes each in ten millilitres of antibody wash to remove residual primary antibody, 
the membranes were re-incubated for 30 minutes in five millilitres of the secondary antibody 
solution. The choice of the secondary antibody depended on the primary antibody (i.e. mouse 
or rabbit). In order to remove residual secondary antibody the membranes were washed three 
times for five minutes followed by a final wash procedure of three two-minute washes with 
distilled water. 
In the last step, the membranes were incubated with 5 ml of chromogenic substrate for one to 
60 minutes without agitation. With our antibodies, 15 minutes were enough to visualise the 
bands.  
The membranes were then washed for a final three times in ten millilitres of distilled water for 
two minutes before placing them on a clean filter paper to dry in the open air at room 
temperature.  
The stained bands were visually compared to those of the marker loaded during 
electrophoresis to estimate size. The process was performed with the above mentioned β-actin 
protein-loaded membrane. Beta-actin was therefore also useful in detecting eventual errors 
such as incomplete transfers. 
2.3.4 Immunocytochemistry (ICC) 
The expression of CXCL12 in the studied cell lines was determined by immunocytochemical 
staining. The detection procedure consisted of cytocentrifugation prior to the staining itself. 
2.3.4.1 Preparation of Cytospin slides 
Cell staining began with preparation of the enriched suspension. To avoid stromal CXCL12 in 
background, the cells were starved in medium without FCS for 24 hours. After 24 hours, the 




medium was discarded, and the cells were washed with PBS and incubated with trypsin. Then 
cells were transferred to a fresh Falcon
®
-tube with fresh medium. An appropriate cellular 
suspension was prepared and the cells were counted according to the procedure described in 
Chapter 2.3.1.4. For our purpose, 3 x 10
4
 cells/ml were needed for the preparation of each 
superfrost glass slide. 
The centrifuge consists of 12 “Cytospin-sample chambers”. For each superfrost glass slide, 
100 μl of each cellular suspension was added. The cells (3 x 10
3
 cells/ml) were centrifuged for 
five minutes at 1500 rpm using program 1 (predefined for this purpose according to the 
manufacturer´s protocol). After the cells had been centrifuged the slides were removed from 
the centrifuge and examined under a light microscope to confirm homogenous separation. 
Afterwards the slides were dried at room temperature over-night. 
2.3.4.2 Immunocytochemical CXCL12 staining method 
In order to prepare the glass slides with the cellular monolayer for the immunochemical 
staining procedure, they were fixed in -20°C acetone for 10 minutes and then washed in a 
Wash-Buffer for a few minutes. The samples were incubated for 45 minutes at room 
temperature with the primary monoclonal mouse anti-CXCL12 antibody (Table 2.5) diluted 
1:2000. After washing, the enhancement reagent “PostBlock” was applied and incubated at 
room temperature for 20 minutes. A second wash was followed by the application of the 
“HRP-polymer” with 30 minutes incubation at room temperature. Any excess of unbound 
HRP-polymer was thoroughly washed off after incubation. The addition of the chromogenic 
substrate started the enzymatic reaction of the peroxidase, which led to colour precipitation 
wherever the primary antibody was bound. 
For the final visualisation, a 20-power Olympus light microscope equipped with a camera was 
used to obtain photographic documentation of the observed images. If cells expressed 
CXCL12 this was seen as a red-brown staining either of the cell surface, cytoplasm or both. 
2.3.5 Colony formation unit assay (CFU assay) 
The colony-forming unit (CFU) assay is the basic method of tumour radiobiology to 
determine the clonogenicity of irradiated cells by their ability to form a colony in a defined 
growth environment. It is the “gold standard” for in vitro studies (Joiner and Kogel 2009). 




In general, the in vitro CFU assay for radiosensitivity is based on seeding cells, irradiating 
them, and then after a suitable period of incubation counting the number of colonies. The 
plating efficiency (PE) is calculated by dividing the number of colonies by the number of 
seeded cells. 
Following determination of PE, the fraction of cells surviving a given treatment (SF) was 
calculated by normalizing PE after a given dose to that of the control non-irradiated plates:  
The cytotoxic effect of radiation on cells is commonly described by a cell survival curve. The 
survival curves were evaluated for three tumour and one control cell lines irradiated in a range 
of doses from 0 to 4 or 6 Gy. Since the number of colonies became too low for trustworthy 
quantification, higher doses of irradiation could not be used. Because the number of seeded 
cells is not directly proportional to the number of resulting colonies, even in control samples, 
increase in number of seeded cells failed to overcome this dose limitation. The survival 
fraction as a function of dose was plotted on a logarithmic scale (y axis), against dose on a 
linear scale (x axis), resulting in a survival curve.  
2.3.5.1 Seeding procedures 
A single-cell suspension was prepared for each cell line (except for DF-19 cell line because of 
its poor colony forming capacity and the tendency to differentiate during the incubation 
period) following the procedure described above (see Chapter 2.3.1.4). Depending on the 
different radiation doses to be tested the single-cell suspension was divided into aliquots. One 
group of cells was defined as a control for the assay and was kept without irradiation and 
eventually without any kind of particular treatment. For treatment with CXCL12 or 




AMD3100, appropriated concentrations of CXCL12 or AMD3100 solution were prepared in 
the medium of each cell lines (see Table 2.8). 
Suspensions with the desired total number of cells were prepared in 15 ml sterile plastic tubes. 
The cells underwent subsequent X-ray irradiation in the laboratory. The doses were 
previously defined as 0.5, 2, 4, or 6 Gy with a dose rate of 1 Gy/min. The control cells were 
not irradiated. 
After irradiation, the cell suspensions were dispensed in 50 ml culture flasks in quadruplicate 
for each treatment condition. Depending on the employed radiation dose, 300 to 3000 cells 
were seeded per flask. 
Treatment with CXCL12  
When treated with CXCL12, the cells were incubated for two hours in a medium lacking FCS 
and were then trypsinised. Suspensions of 2 x 10
5
 cells/ml were prepared in medium lacking 
FCS. The cells were irradiated (0 to 6 Gy) and 500 microlitres of each cell suspension was 
incubated in 48-well plates. Each well, except the control well (cells in medium), was treated 
with 100 ng/ml CXCL12 (cells in medium with CXCL12). The plate was incubated for 48 
hours at 37°C in a 5% CO2-atmosphere. After the incubation period, the cells were trypsinised 
and counted and 300 to 3000 cells/flask were seeded in a quadruplicate for each treatment 
condition. 
Treatment with CXCR4 antagonist (AMD3100) 
For treatment with AMD3100, we used two CXCR4-positive cell lines, ZMK-1 and FaDu. 
The cells were first incubated for two hours in medium lacking FCS and then trypsinised. 
Suspensions of 2 x 10
5
 cells/ml were prepared in medium lacking FCS. The cells, except the 
control cells, were treated with 5 µg/ml AMD3100 for 30 minutes and then incubated at 37°C 
and 5% CO2. The cells were irradiated (0 to 4 Gy) and 1 ml of each cell suspension was 
incubated in a 48-well plate for 26 hours at 37°C and 5% CO2. After incubation, the cells 
were trypsinised and counted and 300 to 2000 cells/flask were seeded in a quadruplicate for 
each treatment condition.  
After seeding into the culture flasks, cells were incubated at 37°C and 5% CO2 for a period 
between 8 to 14 days depending on the cell growth capacity of each line. All plates were 




regularly observed under the microscope and colony growth was evaluated. The colonies were 
then fixed and stained as described in Chapter 2.3.5.3.  
2.3.5.2 Cell irradiation 
A RS 225 X-ray Research System (Gulmay Medical Systems, Camberley, Surrey, UK) was 
used for irradiation. The cells were irradiated with a tube voltage of 200 kV and a current of 
15 mA filtered by a 0.5 mm thick copper sheet at a temperature of 22 to 24 °C. The table 
height, defined as a distance between the table and the radiation source, was altered according 
to the preferred dose rate. This height was 500 mm and 351 mm for a dose rate of 1 Gy/min 
and 2 Gy/min, respectively.  
2.3.5.3 Colony fixation and crystal violet staining  
After the cell culture medium was removed from the culture flasks, four millilitres of 70% 
ethanol were pipetted into each flask and left there for 20 minutes. The ethanol was removed 
and the flasks were dried in an incubator over-night. The fixed cells were stained with 0.1% 
crystal violet solution. Four millilitres of the crystal violet solution were added to each flask. 
After 20 minutes the solution was removed and excess stain was washed away with water. 
This procedure made the colonies visible and easily counted. Sterile conditions were not 
required for fixation and staining.  
2.3.5.4 Counting of colonies 
Plates with stained colonies were examined under the light microscope. A cluster of blue-
stained cells was considered a colony if it comprised at least 50 cells. It was important to keep 
this cut-off constant to avoid variations between experiments. All the cells of the colony were 
the progeny of a single cell. 
2.3.5.5 Cell survival curves 
To establish cell survival curves, the fixed and stained colonies were counted and the values 
of the surviving fraction for each treatment condition were calculated as described above. 
Each experiment and different treatment condition was repeated three times and the cells from 




each were seeded in quadruplicate. Afterwards mean values (expressed as points in the 
curves) were calculated and standard errors (SE) were plotted as error bars. If the error bars 
are not visible on the graph, they are smaller than the size of the point. Using Kaleidagraph® 
(version 4.1) the calculated surviving fractions were transformed graphically into a semi-
logarithmic scale representation. The abscissa represents the radiation doses on a linear scale, 
and the ordinate represents the surviving fractions on a logarithmic scale. The shape of the 
survival curve is unique for each cell line helping to evaluate cell behaviour under different 
irradiation conditions associated with or without other treatment regimens. 
2.3.5.6 Data analysis 
Survival curves, each referring to its specific control, were fitted to the data points using a 
linear-quadratic approach with: 
           
where D represents the applied radiation dose and α and β are proportionality factors. The 
dose-modifying factor (DMF) was calculated by the ratio of the radiation dose in the absence 
or presence of CXCL12 and AMD3100 to achieve the same cell survival rate.  
2.3.6 Cell viability assay - Cell Titer Blue
®
 (CTB assay) 
The CTB assay is a cell viability assay that provides a homogeneous, fluorometric method to 
monitor cell viability and cell metabolic activity in multiwell plates. The assay is based on a 
redox reaction. Viable, metabolically active cells, can convert resazurin (dark blue with little 
intrinsic fluorescence activity) into its highly fluorescent product, resorufin (pink, highly 
fluorescent molecule) (Promega, Technical Bulletin, revised 6/09, Figure 2.1). The intensity 
of the fluorescence is proportional to the number of viable cells and their metabolic activity. 
Sterile 96-well black plates with clear bottoms were used for analysis.  






Figure 2.1: Conversion of resazurin with little fluorescence activity to resorufin with highly 
fluorescence activity by viable cells.  The intensity of the fluorescence produced is proportional to 




2.3.6.1 Determination of optimal incubation time and radiation dose within CTB 
assay 
Test 1: Optimal incubation time 
Before setting up the 96-well plates for the cell viability assay, four different incubation times 
(26, 48, 72, and 96 hours) were tested to find the best possible incubation time. This 
experiment was performed only for control cell line HaCat and tumour cell line ZMK-1.  
First, a suspension of HaCat and ZMK-1 cells was prepared and maintained in a 15 ml plastic 
tube. One tube contained a suspension of the control cells without irradiation; after preparing 
the cell suspension, the second tube was irradiated. The irradiation was performed as 
described in Chapter 2.3.5.2. A total dose of 4 Gy was delivered with a dose rate of 1 Gy/min. 
After the irradiation the cells were seeded into wells; 5000 cells per well for HaCat and 6000 
cells per well for ZMK-1 (see Table 2.12, green area). 





Test 2: Optimal radiation dose 
Suspensions containing the necessary number of cells were prepared and maintained in 15 ml 
plastic tubes. One tube contained cells for the control group (no irradiation); the other tubes 
were irradiated. After delivering with a dose rate of 2 Gy/min total doses of 2, 4, 6, 8, 10 and 
12 Gy the cells were seeded into wells, with 5000 cells/well for HaCat and 6000 cells/well for 
ZMK-1 (see Table 2.12, green area). 
Test 3: Combination of optimal incubation time and radiation dose 
Due to non-optimal incubation times for observing the effect of irradiation on cell viability, 
the assay was repeated for all five cell lines with a longer incubation time, i.e. for one week. 
For this test, a radiation dose of 8 Gy was selected as the optimal dose. For observing the 
effect of irradiation on cell viability, we decided to reduce the cell density to 2000 cells per 
well. In this last test, the cells were seeded in wells and the plate was then irradiated. Two 
plates were prepared; one 8 Gy irradiated plate, and one non-irradiated plate. 
With the purpose of completing and homogenizing the volume per well, a total volume of 100 
μl of each cell suspension per well was added to each well. The outer wells on all sides were 
loaded with cell-free medium (cell-free medium: M, Table 2.12). The contents of the wells in 
the first column (column 1, blue area B1-G1) were used as blank samples to determine 
background fluorescence. The green area represents the different conditions investigated. For 
each experiment and condition the test was done in triplicate (Table 2.12). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A M M M M M M M M M M M M 
B M 
1 2 3 4 5 6 7 8 9 10 
M 
C M M 
D M M 
E M 
11 12 13 14 15 16 17 18 19 20 
M 
F M M 
G M M 
H M M M M M M M M M M M M 
Table 2.12: Schematic representation of a 96-well plate seeded with cells and medium 
 




The prepared plates (irradiated and non-irradiated) were incubated for one week under 
standard incubation conditions (37°C and 5% CO2). At the end of the incubation period, the 
plate was removed from the incubator, 20 μl of CTB Reagent was added cells in culture as 
well as 6 wells in the column 1 (Blank wells) following the manufacturer’s guides, and the 
plate incubated again for one hour at 37°C before reading the 96-well plate on a fluorometer 
at 560 nm excitation and 590 nm emission. 
2.3.6.2 Investigating various treatments on cell viability 
The notion of optimal radiation dose and incubation time permits to optimise the experimental 
process. If more treatment combinations are required in the same experiment, e.g. irradiation, 
CXCL12 and/or AMD3100, one plate is not irradiated and the other is irradiated allowing 
each treatment condition to be analysed with and without irradiation. 
To begin with, a cell suspension containing 2 x 10
4
 cells/ml was prepared and divided in four 
15 ml plastic tubes. The first tube was treated with 100 ng/ml of CXCL12, a second tube with 
5 µg/ml of AMD3100, a third tube with both of them. The last tube did not contain any drug. 
All tubes were incubated for 30 minutes at 37°C and 5% CO2. From each tube 100 µl of the 
cell suspension (2000 cells/well) was pipetted in two sterile 96-well black plates with clear 
bottoms; each experimental condition was performed in triplicate. One of this 96-well-plate 
was irradiated. A total dose of 8 Gy was delivered with a dose rate of 2 Gy/min. 
After a one-week incubation time, the plates were removed from the incubator and CellTiter-
Blue
®
 Reagent was added to the wells. The plates were gently shaken for ten seconds and 
returned to the incubator for one more hour at 37 °C for one hour. The experiment was 
performed twice for each cell line and the data were analysed following the procedure 
described below (see following Chapter 2.3.6.3). 
2.3.6.3 Data analysis 
The fluorescence analysis was performed with a Wallec1420 VICTOR
TM
 plate reader. The 
dye was excited with a 560 nm wavelength and the emissions measured at 590 nm. The 
obtained data were imported into Microsoft Office and the following calculations were 
performed: background fluorescence was subtracted from the raw fluorescence results of all 




wells. The averages and the standard deviations of the triplicate determinations were 
calculated. 
2.3.7 Migration assay 
One of the most commonly used migration assays is the Boyden chamber/Transwell assay 
(Figure 2.2). This method is used to quantify the migration of cells exposed to 
chemoattractants such as chemokines. The chamber includes two compartments separated by 
a microporous filter (8 µm) through which the cells migrate.  
The relevant chemoattractant solution is placed in the lower chamber to create a chemotactic 
gradient while the cells to be tested are incubated in the upper chamber. After an appropriate 
incubation time, the upper surface of the filter is scraped twice with cotton swabs to remove 
non-migrating cells. Migrated cells on the lower surface of the membrane are fixed and 
stained by Diff-Quick
®
 kit. Five to seven random photographs were taken of each membrane 
with an Olympus light-microscope coupled with a camera, and the cells in each photograph 
were counted and quantified using the “ImageJ” software.  
 
 
Figure 2.2: A ThinCertTM  cell culture insert is placed in the well of a multiwell cell culture plate, 
thus forming a migration chamber.  The migration chamber consists of an upper and lower 
compartment with a porous PET membrane in-between. Cells may actively migrate from the upper to 
the lower compartment. The figure was taken and modified from  (Oppegard et al. 2010). 




2.3.7.1 Determination of optimal concentrations of CXCL12 and AMD3100  
Best concentration of CXCL12 
This experiment was performed with the CXCR4-positive tumour cell line (ZMK-1). 8 x 10
4
 
cells were seeded into the insert. CXCL12 as chemoattractant was added to the lower chamber 
in the concentrations 0, 25, 50 and 100 ng/ml. The cells were allowed to migrate for 26 hours 
at 37°C and 5% CO2. 
Best concentration of AMD3100 
This experiment was also performed with ZMK-1 cell line. The cells were incubated with six 
different concentrations of AMD3100, i.e. 0, 1, 5, 12.5, 25 and 50 µg/ml for 26 hours at 37°C 
and 5% CO2. At the end of the incubation time 8 x 10
4
 cells were seeded into the insert. 
CXCL12 (100 ng/ml, optimal concentration determined in the experiment described above) 
was added to the lower chambers. The cells were allowed to migrate for 26 hours at 37°C and 
5% CO2.  
2.3.7.2 Influence of irradiation and CXCL12 on cell migration  
Cells were initially starved of serum for two hours. A cell suspension containing 16 x 10
4
 
cells was prepared and kept in four 15 ml plastic tubes. One tube contained cells for the 
control group (non-irradiated cells); the second tube was irradiated at 0.5 Gy; the third and 
fourth tubes were irradiated at 2 and 4 Gy, respectively. 500 µl cell suspensions aliquots from 
each tube (8 x 10
4
 cells) were seeded into serum-free medium in the two inserts. To 
investigate the influence of CXCL12 on cell migration, 100 ng/ml of CXCL12 was added to 
the one of the lower chambers (see Table 2.13, A1-A4, purple area). The remaining lower 
chambers were CXCL12-free (Table 2.13, B1-B4, green area). 
The cells were allowed to migrate for 26 hours at 37°C and 5% CO2. The experiments were 
repeated in duplicate for all cell lines. The results are expressed as the mean number of 
migrated cells ± standard deviation. Statistical differences were determined by Student’s t-
test. A value of p<0.05 was considered to indicate a statistically significant difference. 




2.3.7.3 Influence of AMD3100 on CXCR4-positive migrating cells 
This experiment was only performed with the CXCR4-positive tumour cell lines (ZMK-1 and 
FaDu). Cells were initially starved of serum for two hours. A cell suspension containing 16 x 
10
4
 cells was prepared and maintained in eight 15 ml plastic tubes. Two tubes contained cells 
for the non-irradiated control group. For each radiation dose (0.5, 2 and 4 Gy) two tubes were 
prepared, i.e. for each dose one tube was treated with AMD3100 (5 µg/ml) for 30 minutes at 
37°C and 5% CO2 and the other tube was untreated (see Table 2.14, purple area: treated and 
green area: untreated cells). To control for AMD3100 influence on non-irradiated cells one of 
the control tubes was also treated with AMD100 (see Table 2.14, blue area).  
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Table 2.13: Schematic illustration of a 24-well transwell plate seeded with irradiated and non-irradiated cells. 
100 ng/ml of CXCL12 was added in the lower chamber of purple area, which was not available in green area.  
Table 2.14: Schematic illustration of a 24-well transwell plate seeded with irradiated and non-irradiated 
cells. 100 ng/ml of CXCL12 was added in all lower chambers except A1 for control. Irradiated cells in the 
purple area were treated with 5µg/ml of AMD3100. However, irradiated cells in the green area were 
untreated. 




After the six treated cell suspensions had been irradiated, 500 µl cell suspension (8 x 10
4
 
cells) aliquots from all nine tubes were seeded into serum-free medium. To investigate the 
inhibitory effect of AMD3100 on cell migration, 100 ng/ml of CXCL12 was added to all 
lower chambers except one control chamber (see Table 2.14, A1). The cells were allowed to 
migrate for 26 hours at 37°C and 5% CO2. The experiments were repeated in triplicate.  
2.3.7.4 Data analysis 
The measurements and numbers of migrated cells were determined in duplicate to analyse the 
impact of the CXCL12 gradient on cell migration. The experiments on the inhibitory effect of 
AMD3100 on CXCR4-positive cell lines were repeated three times. The results are expressed 
as the mean number of migrated cells ± standard deviation. The differences between two 
groups were compared by Student´s t-test. One-way ANOVA was used to compare three or 







3.1 In vivo analysis of HNSCC biopsies 
3.1.1 General HNSCC patient data 
In the patient collective, both genders were included. The numbers of men and women were 
197 (85%) and 36 (15%), respectively, which correspond to a male-to-female ratio of 5.7:1 
(Table 3.1). Four different primary tumour sites were present in the patients. These were oral 
cavity, oropharynx, hypopharynx and larynx. Oropharyngeal carcinomas were the most 
common ones (99 cases, 42.5%), followed by oral cavity (63 cases, 27%) and hypopharyngeal 
carcinomas (45 cases, 19.3%) (Table 3.1).  
         Table 3.1: Pre-treatment characteristics of study patients  
Characteristic Patientsn (%) 
Gender  
 Male 197 (85) 
 Female  36 (15) 
Tumour localization  
 Oral cavity 63 (27) 
 Oropharynx 99 (42.5) 
 Hypopharynx 45 (19.3) 
 Larynx 26 (11.2) 
UICC stage  
 II 7 (3.0) 
 III 16 (6.9) 
 IV A/B 189/21 (90.1) 
T-status  
 1 7 (3.0) 
 2 17 (7.3) 
 3 39 (16.7) 
 4 170 (73) 
N-status  
 0 35 (15) 





 2 149 (64) 
 3 22 (9.4) 
Histological grading  
 1 11 (4.7) 
 2 187 (80.3) 
 3 35 (15) 
Previously untreated tumours were staged according to the current classification of the Union 
Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer 
(AJCC) (Brandwein–Gensler and Smith 2010). All tumours were also staged according to the 
TNM staging system (Sobin and Compton 2010). The pathologic stage, tumour diameter, and 
nodal status were obtained from the primary pathology reports.  
The distribution of the histopathological tumour grades was: Grade 1: 11 patients; Grade 2: 
187 patients; and Grade 3: 35 patients (Table 3.1).  
3.1.2 Analysis of CXCL12, CXCR4 and p16
INK4A
 expression at the protein level 
by immunohistochemical staining 
In order to investigate the in vivo relevance of the expression of CXCL12, CXCR4 and 
p16
INK4A
, immunohistochemical analyses were performed on 233 primary HNSCC tumour 
tissue samples. The individual results of the staining are expressed as a score for each patient 
and each marker (see Chapter 2.2.2.1). This has the advantage that the evaluations of the 
  
 
Figure 3.1:  Representative IHC staining of CXCL12 and CXCR4 in HNSCC tumour specimens.  
In this staining system, the CXCL12 and CXCR4 are stained red and the nuclei are stained blue  A) 
CXCL12 was expressed in the cytoplasm and/or in the nucleus. B) CXCR4 was also expressed in the 







analysis could be directly and simply compared with other parameters that were generated in 
this study. First of all, the expression of the three markers was correlated with the patient’s 
pre-treatment data.  
The analyses were able to detect expression of CXCR4 and CXCL12 in 233 and 229 patients, 
respectively (Figure 3.1). For 4 patients there was not enough material for CXCL12 staining. 
The scores for the expression intensity of CXCR4 ranged from 0 to 210. Absent or very low 
expression with a score ≤ 10 was found in about one third of the patients (n = 79, 33.9%). For 
further analysis, the data were divided into three groups: a score between 15 and 70 
represented a medium expression (n = 79 patients, 33.9%) and a score > 70 a high expression 
(n = 75 patients, 32.2%). CXCL12 expression was observed less frequently, as 132 patients 
(56.7%) were negative for the marker. In the CXCL12 expression analyses we only 
differentiated between negative and positive samples. 
The analysis of p16
INK4A
 expression showed that 102 of the 233 (44%) samples had 
cytoplasmic and/or nuclear staining. Interestingly, there was a significant increase in 
p16
INK4A
-positive HNSCC patients in this cohort study over the period from 1992 to 2011 
(Figure 3.2, p=0.00091). 
 
 










Figure 3.3: Representative IHC staining of p16 INK4A in HNSCC tumour specimens. In this staining 
system, the p16 INK4A is stained red and the nuclei are stained blue. Tumours were classified as: A) 
continuous and diffuse cytoplasmic and/or nuclear staining, B) weak and focal (patchy) cytoplasmic 








 Based on the evaluation, there were three different phenotypes for p16
INK4A
 
immunoreactivity (Figure 3.3 A-C), namely diffuse positive cytoplasmic and/or nuclear 
staining (Figure 3.3 A), weak and focal (patchy) positive cytoplasmic and/or nuclear staining 
(Figure 3.3 B), and negative staining (Figure 3.3 C). Diffuse positive staining was found in 62 
of the 233 (27%) samples. Forty of the 233 (17%) samples had weak focal positive staining. 
The remaining 135 samples were negative for the p16
INK4A
 expression. 
3.1.2.1 Association of CXCL12, CXCR4 and p16
INK4A
 expression with pre-treatment 
parameters 
The association of CXCR4, CXCL12 and p16
INK4A
 expression with clinicopathological 
characteristics is shown in Table 3.2 and Table 3.3.  
CXCR4  
The expression of CXCR4 was positively and significantly associated with the patients´ age; 
patients older than the median age of the cohort showed a significant increase in CXCR4 
positivity (p=0.0035). However, the expression of this protein did not show any statistically 
relevant correlation with other pre-treatment parameters, such as gender, primary tumour 
localisation, T/N status or UICC stage. 
Table 3.2: Association of CXCL12 and CXCR4 expression with clinicopathological characteristics of 233 
Patients with inoperable HNSCC  
Characteristics Number of patients (%) p-
value 




 Total CXCR4 expression  CXCL12 expression  
  low 
≤10 
median       



















Age     0.0035   0.90 






























Gender     0.65   0.83 


























Tumour localization     0.76   <0.001 




















































Histological grading     0.33   0.075 







































T-status     0.88   0.51 




































17 (43.6)  













N-status     0.78   0.025 


















The expression of CXCL12 was significantly correlated with tumour localisation (p<0.001). 
Tumours of the oral cavity were predominantly CXCL12-negative (84.1% negative vs. 15.9% 
positive, Table 3.2). In contrast, tumours located either in the oropharynx, the hypopharynx or 
the larynx showed nearly similar proportions of CXCL12-positive and negative samples. It 







 expression was not significantly associated neither with age at diagnosis, gender, 
tumour localization, histological tumour grade nor UICC stage. There were no statistically 
significant differences in these parameters between patients with and without p16
INK4A
 
expression (Table 3.3). 





































UICC stage     0.53   0.30 











































Table 3.3: Correlation between p16INK4A expression and clinicopathological characteristics of 233 patients 
with inoperable HNSCC  (reproduced from (Tehrany et al. 2015))   
3.1.2.2 Correlation between CXCL12, CXCR4 and p16
INK4A
 expression in HNSCC 
tumours 
In HNSCC tumour samples, for which the expression of CXCL12, CXCR4 and p16
INK4A
 was 
evaluated by immunohistochemical staining, the correlation among CXCL12, CXCR4 and 
p16
INK4A
 expression was investigated. There was a significant positive correlation between 
Characteristics Patients (%) Number of patients (%) p-value 
 Total P16INK4A expression  





Total n = 233 131 (56.2) 102 (43.8)  
Age    0.146 
 < Median 116 (49.7) 71 (61.2) 45 (38.8)  
 > Median 117 (50.2) 60 (51.3) 57 (48.7)  
Gender    0.586 
 Male 197  (84.7) 109  (55.3) 88 (44.7)  
 Female 36 (15.3) 22 (61.1) 14 (38.9)  
Tumour localization    0.066 
Oropharynx 99 (42.5) 50 (50.5) 49 (49.5)  
Hypopharynx 44 (18.9) 21 (47.7) 23 (52.3)  
Larynx 27 (11.6) 17 (63.0) 10 (37.0)  
Oral cavity 63 (27.0) 43 (68.3) 20 (31.7)  
Histological grading    0.203 
 G1 11 (4.7) 6 (54.6) 5 (45.4)  
 G2 187 (80.3) 110  (58.8) 77 (41.2)  
 G3 35 (15.0) 15 (42.9) 20 (57.1)  
UICC stage    0.08 
 II 7 (3.0) 1 (14.3) 6 (85.7)  
 III 16 (6.9) 9 (56.2) 7 (43.8)  







 expression and CXCL12 and CXCR4 expression. However, no significant 
association between CXCL12 expression and CXCR4 was seen. Additionally, as shown in 
Figure 3.4, the degree of CXCR4 expression and positivity for CXCL12 correlate 
significantly with positive expression of p16
INK4A  





Figure 3.4: Correlation between p16 INK4A positivity and CXCL12 and CXCR4 expression.  In the 






3.1.3. Correlation between p16
INK4A
 expression and HPV status in HNSCC 
tissue samples 
Next, 233 HNSCC tissue samples were examined for the presence of HPV DNA using broad 
spectrum PCR and nested-PCR to determine whether HPV detection differs when different 
primer sets are used. First of all, the two major consensus primer sets used for PCR 
amplification of HPV DNA were compared, the PGMY 09/11 primer sets and the 
GP5+/GP6+ primers. To monitor DNA quality, the specimens were also amplified with the ß-
globin primers PC04 and GH20 (268 bp in size) (Figure 3.5 A). Fifty-four of the 233 (23%) 
samples showed either only weak signals or no amplification of the ß-globin. However, to 
avoid missing samples that contain HPV DNA, we decided to subject these 54 samples to 
nested-PCR as well. Furthermore, the fragments of 450 bp and 140 bp in size were amplified 
in all samples using PGMY 09/11 and GP5+/GP6+ primers, respectively (Figure 3.5 B and 
C). In this study the PGMY 09/11 and GP5+/GP6+ consensus primer sets showed a 
completely different sensitivity, as defined by the ability to detect HPV DNA. Although 44 
(19 %) specimens were HPV DNA positive in PCR experiments using the GP5+/GP6+ 
primers, no sample showed HPV DNA positivity in PCR experiments using the PGMY 09/11 
primers except for the positive control with a high concentration of HPV-6 DNA.  
Of note, we did not observe multiple infections. Furthermore, we sequenced the positive 
nested amplicons to confirm correct HPV genotype amplification (see methods Chapter 
2.2.2.5). 
Nested-PCR was performed to validate the IHC-based detection of p16
INK4A
 expression. The 
correlation between immunohistochemical analysis of p16
INK4A
 expression and HPV subtypes 
is summarized in Table 3.4.  
Although the FFPE samples were old, we were able to detect HPV DNA (L1 consensus) in 44 
(19 %) samples (42 samples were sequenced as HPV-16 and 2 samples as either HPV-6 or 
HPV-11). Based on the immunohistochemical analysis cytoplasmic and nuclear p16
INK4A
 









Figure 3.5: PCR results with 3 primer sets on HNSCC specimens.  A) PCR with PC04 and GH20 ß-
globin primers to monitor DNA quality (expected size of 268 bp in size). B) Board spectrum PCR 
amplification yield with PGMY 09/11 primer sets for the L1 region of HPV g enome (expected size of 
450 bp in size). C) nested-PCR with GP5+/GP6+ primers as nested-PCR (expected size of 140 bp in 









The correlation between p16
INK4A
 expression and HPV DNA in the tumour cells was highly 
significant (p<0.01), and 41 of 42 (98%) samples positive for HPV-16 (a high-risk HPV 
subtype) showed p16
INK4A
 immunoreactivity. However, in one sample there was no p16
INK4A
 
immunoreactivity despite HPV-16 DNA being detected (details given in Table 3.4). There 




Table 3.4: HPV detection and P16 INK4A expression (reproduced from (Tehrany et al. 2015)) 
 
 Total Diffuse Focal Negative 
HPV-16 42 31 10 1 
HPV-6/11 2 1 0 1 
HPV negative 189 30 30 133 
Total 233 62 40 135 
3.1.4 Treatment outcome and high-grade acute organ and hematotoxicity in 
HNSCC patients 
In this study, the response to treatment was classified as complete remission (126 patients, 
54.1 %), partial remission (48 patients, 20.6 %), no change (19 patients, 8.2 %), and 
progression (20 patients, 8.6 %). Twenty patients (8.6%) were lost during follow-up, and no 
data are available concerning the state of disease at the end of therapy.  
At the end of the study, 185 patients (79.4%) had died due to tumour-related causes (132 
patients) or from other intercurrent disease (53 patients). Loco-regional reoccurrence were 
seen in 66 of the 233 patients (28.3%), and distant metastases occurred in 29 of 233 patients 
(12.5%) during follow-up. At the end of the study, 48 patients (20.6%) were still alive. The 
three- and five-year OS rates were 27.1% and 23.2%, respectively.  
In addition to treatment outcome, treatment-related acute organ toxicity and hematotoxicity 





Table 3.5: Incidence and grading of acute organ and hematotoxicity ( reproduced from (Tehrany et al. 2015)) 
Acute organ toxicity occurred during R(C)T as follows and is summarized in table 3.5; 231 of 
the 233 patients developed mucositis (58x grade 1; 131x grade 2; 42x grade 3), a skin reaction 
was seen in 232 patients (82x grade 1; 135x grade 2; 15x grade 3), dysphagia was noted in 
196 patients (92x grade 1; 70x grade 2; 34x grade 3) and nausea was seen in 51 patients (36x 
grade 1; 15x grade 2).  
Acute hematotoxicity during R(C)T appeared as follows: anaemia grade 1 was seen in 41, 
grade 2 in 59, and grade 3 in 11 patients; leukopenia grade 1 was observed in 35, grade 2 in 
42, grade 3 in 26, and grade 4 in 7 patients; thrombocytopenia grade 1 was noted in 19, grade 
2 in 7, grade 3 in 3 patients and grade 4 in one patient (Table 3.5).  
3.1.4.1 Correlation of cytoplasmic expression of CXCL12, CXCR4 and p16
INK4A 
with 
acute toxicity during treatment 
Figure 3.6 illustrates the correlation between the expression of the three investigated proteins 
(CXCL12, CXCR4 and p16
INK4A
) and high-grade toxicity during R(C)T. Acute organ toxicity 
and hematotoxicity were evaluated weekly for the entire duration of R(C)T. The evaluation 
was continued every second week after the end of therapy until acute toxicity according to the 
scoring system (Common Toxicity Criteria, CTC) was no longer detectable. For this analysis, 
due to a significantly impaired of quality of life, acute toxicity was scored as HGAOT or 
 Number of patients (%) 
Type None Grade 1 Grade 2 Grade 3 Grade 4  
Acute organ toxicity      
 Mucositis 2 (0.9) 58 (24.9) 131 (56.2) 42 (18.0) 0 (0.0) 
 Skin reaction 1 (0.4) 82 (35.2) 135 (57.9) 15 (6.4) 0 (0.0) 
 Dysphagia 37 (15.9) 92 (27.8) 70 (30.0) 34 (14.6) 0 (0.0) 
 Nausea 182 (78.1) 36 (15.5) 15 (6.4) 0 (0.0) 0 (0.0) 
Acute hematotoxicity      
 Anaemia 122 (52.4) 41 (17.6) 59 (25.3) 11 (4.7) 0 (0.0) 
 Leukopenia 123 (52.8) 35 (15.0) 42 (18.0) 26 (11.2) 7 (3.0) 





HGAHT if one or more of the acute toxicity items were graded as CTC >2. HGAOT of grade 
III ensued in 77 of the 233 cases (33%). Additionally, HGAHT of grade III-IV occurred in 42 
of the 233 cases (18%) (Figure 3.6). 
There was no significant correlation between HGAHT and the expression of any of the three 
proteins with p=0.55, p=0.97 and p=0.46 for CXCL12, CXCR4 and p16
INK4A
, respectively 
(Figure 3.6 A, C, E). Moreover, HGAOT also showed no association with CXCL12 and 
CXCR4 status with p=0.34 and p=0.49 for CXCL12 and CXCR4, respectively (Figure 3.6 B, 
D). In contrast, the expression of p16
INK4A
 was significantly associated with the occurrence of 
HGAOT during R(C)T (Figure 3.6-F, p=0.011). The correlation between HGAOT and 
p16
INK4A


















Figure 3.6: Correlation between cytoplasmic expression of CXCL12, CXCR4 and p16 INK4A and 
HGAOT and HGAHT during R(C)T.  Expression of these three proteins did not correlate with 
HGAHT (A, C, E). Only for p16 INK4A expression there was a statistically significant correlation with 
HGAOT (p=0.011) during R(C)T (F). No significant correlation between expression of CXCL12 and 
CXCR4 with HGAOT was noted (B, D). HGAHT: high-grade acute hematotoxicity, HGAOT: high-
grade acute organ toxicity, n: number of patients with positive  or negative occurrence of HGAOT or 
HGAHT.  
 
The distribution of acute toxicity symptoms in patients with positive or negative expression of 
p16
INK4A
 during R(C)T was as follows: out of the 77 patients with higher than grade 2 acute 
organ toxicity, 43 patients (42.2%) expressed p16
INK4A 
(p = 0.011). 
Table 3.6: Organ toxicity in relation to p16 INK4a expression (reproduced from (Tehrany et al. 2015)) 
 Number of patients (%) P-value 
Type Total P16
INK4a
 expression  
  Negative  Positive  
Mucositis     0.609 
≤ grade 2 191 (82.0) 109 (83.2) 82 (80.1)   
> grade 2 42 (18.0) 22 (16.8) 20 (19.9)   
Skin reaction    0.592 
≤ grade 2 218 (93.6) 124 (94.7) 94 (92.2)  
> grade 2 15 (16.4) 7 (5.3) 8 (7.8)  
Dysphagia    0.001 
≤ grade 2 199 (85.4) 121  (92.4) 78 (76.4)  
> grade 2 34 (14.6) 10 (7.6) 24 (23.6)  
Nausea    0.524 
   grade 0 182 (78.1) 100 (76.3) 82 (80.1)  
≥ grade 1 51 (21.9) 31 (23.7) 20 (19.9)  
Organ toxicity    0.011 
≤ grade 2 156 (67.0) 97 (74.1) 59 (57.8)  
> grade 2 77 (33.0) 34 (25.9) 43 (42.2)  
Overall, 20 of the 42 patients with higher than grade 2 mucositis during R(C)T were positive 
for p16
INK4A
 expression (Table 3.6, p=0.609). Of the 15 patients with a higher than grade 2 
skin reaction, eight patients expressed p16
INK4A
 (Table 3.6, p=0.592). Dysphagia higher than 







Furthermore, expression of p16
INK4A
 showed a strong correlation with dysphagia (Table 3.6, 
p=0.001). There were no patients with higher than grade 2 nausea.  
3.1.5 Association of CXCL12, CXCR4 and p16
INK4A
 expression with survival 
data of HNSCC patients 
We analysed the patient survival data to determine whether expression of CXCL12, CXCR4, 
and p16
INK4A
 in head and neck tumours as well as the occurrence of HGAOT during R(C)T 
had any prognostic relevance.  
3.1.5.1 Impact of CXCL12 and CXCR4 expression on patient survival  
In this analysis, no relationship was found between CXCL12 expression, disease free survival 
(DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) 
(Table 3.7). In contrast, Kaplan-Meier analysis of the survival data indicated that patients with 
a tumour expressing CXCL12 had a better OS than those who were CXCL12-negative 
(Figure 3.7, p=0.036). The survival rates were 17% vs. 26%, and 12% vs. 20% (positive vs. 





Univariate Cox regression analyses showed that CXCR4 expression was not significantly 
associated with either OS (p=0.32, Table 3.7) or LRFS (p=0.42, Table 3.7). However, a 
reduced DMFS was significantly associated with a high CXCR4 expression (p=0.034, Figure 
3.8-B, Table 3.7). In addition, a borderline statistically significant correlation was found 
between high CXCR4 expression and decreased DFS (p=0.057, Figure 3.8-A, Table 3.7). The 
association between expression of CXCL12 and CXCR4 and survival data of patients is 





Figure 3.7: Overall survival (OS) related to CXCL12 expression in tumour cells of pre-treatment 
biopsies of patients with HNSCC by Kaplan-Meier analysis. Patients were divided into two groups 









Figure 3.8: Correlation between survival data, and low, medium and high CXCR4 expression in 
pre-treatment biopsies of patients with HNSCC receiving radio(chemo)therapy. A) disease free 
survival, (DFS); B) distant metastasis-free survival (DMFS). The Cox proportional hazard model 
demonstrated that CXCR4 expression was significantly correlated with DMFS (p=0.034). Although an 
association between CXCR4 expression and DFS was also observed, these correlation was not 








Table 3.7: Survival data in relation to CXCL12 and CXCR4 expression  
Characteristics Number of patients (%) p-
value 
Number of patients (%) p-
value 
 Total CXCR4 expression  CXCL12 expression  
  low 
≤10 
median  








Total n = 233 79 (33.9) 79 (33.9) 75 (32.2)  132 (56.7) 97 (41.6)  
RT schedule     0.001   0.53 
Classic 183 (78.5) 73 (39.9) 59 (32.2) 51 (27.9)  104 (58.1) 75 (41.9)  
Intensity-
modulated  
50 (21.5) 6 (12.0) 20 (40.0) 24 (48.0)  28 (56.0) 22 (44.0)  
Chemotherapy     0.44   0.023 
No 62 (26.6) 18(29.0) 26 (41.9) 18 (29.0)  42 (68.9) 19 (31.1)  
Yes 171 (73.4) 61(35.7) 53 (31.0) 53 (31.0)  90 (53,6) 78 (46.4)  
Loco-regional 
recurrence 
    0.42   0.87 
#Events 66 21 18 27  33 32  
60 month survival 0.60 0.64 0.69 0.46  0.55 0.64  
120 month 
survival 
0.57 0.58 0.69 0.46  0.55 0.53  
Distant metastases     0.034   0.52 
# Events 29 7 5 17  17 12  
60 month survival 0.81 0.87 0.88 0.69  0.79 0.81  
120 month 
survival 
0.81 0.87 0.88 0.69  0.79 0.81  
DFS     0.057   0.89 
# Events 81 23 22 36  44 36  
60 month survival 0.51 0.61 0.59 0.33  0.46 0.55  
120 month 
survival 
0.48 0.55 0.59 0.33  0.46 0.50  
OS     0.32   0.036 
# Events 185 68 62 55  110 72  
60 month survival 0.22 0.17 0.25 0.24  0.17 0.26  
120 month 
survival 





3.1.5.2 Impact of p16
INK4A
 expression and the occurrence of HGAOT during R(C)T 
on HNSCC patient survival 
For this cohort we considered the demographic and clinicopathologic characteristics of age at 
diagnosis, gender, tumour stage, and tumour grade (Table 3.3). With regard to these 
characteristics, there was no statistically significant difference between patients with 
p16
INK4A
-positive HNSCC and those with p16
INK4A
-negative HNSCC. We also examined 
survival outcome differences based on p16
INK4A
 expression status in patients with HNSCC 
tumours. We observed that patients with p16
INK4A
 overexpression in their tumours had a 
significantly better OS (p=0.002, Figure 3.9).  
 
  
Figure 3.9: Correlation between cytoplasmic p16 INK4A expression and overall survival (OS) and 
local recurrence-free survival (LRFS).  A) The Cox proportional hazard model demonstrated that 
cytoplasmic p16 INK4A expression was significantly associated with OS in this group of patients 
(p=0.0022). B) The trend towards improved LRFS in the patients with positive p16 INK4A expression was 






Moreover, we evaluated the impact of p16
INK4A
 expression on OS of our HNSCC study cohort 
after therapy and the analysis of acute organ toxicity. It is known that patients with HGAOT 
(CTC >2) including one or more of the items mucositis, skin reaction or dysphagia had better 
OS and locoregional control rates than patients without such reactions (Wolff et al. 2010a).  
Figure 3.10 shows the Kaplan-Meier plots for patients positive and negative for p16
INK4A
 
expression, and with and without the occurrence of HGAOT. These four patient subgroups 
significantly differed in their five-year OS rates. Patients with p16
INK4A
 expression and 
HGAOT had a five-year OS rate of 47%. With only HGAOT, the five-year OS rate was 42%, 
while in patients with p16
INK4A
 expression it was only 20%. The five-year OS rate in patients 
without p16
INK4A
 expression or HGAOT was 10%. In addition, a borderline statistically 
significant correlation was found between P16
INK4A
 expression and LRFS (Figure 3.9, 
p=0.069). 
 
Figure 3.10: Kaplan-Meier plots for patients tested positive and negative for p16 INK4A expression, 
and with and without HGAOT. These four patient subgroups significantly differed in their five -year 
OS rates; Patients with p16 INK4A expression and HGAOT showed better five-year OS rates than patients 
with p16 INK4A expression or HGAOT alone. The five-year OS rates in patients without p16 INK4A 
expression and HGAOT was 10% (n = number of patients,  p16: p16 INK4A, yes: occurrence of HGAOT, 





3.2 The role of CXCL12 and CXCR4 in the migration of irradiated 
HNSCC and control cell lines ( in vitro analysis) 
3.2.1 Characterisation of the cell lines  
The characterisation of three HNSCC and two control cell lines for the expression of 
CXCL12 and CXCR4, and their radiosensitivity and metabolic activity under diverse 
conditions were prerequisite for all subsequent analyses. 
3.2.1.1 CXCL12 and CXCR4 mRNA expression 
Expression of CXCL12 and CXCR4 in the cell lines FaDu, ZMK-1, GR-145 (HNSCC tumour 
cell lines), DF-19 and HaCat (control cell lines) under non-irradiated and irradiated conditions 
has already been determined by real-time PCR at the mRNA level (Wolff et al. 2011a). The 
positivity or negativity of CXCL12 and CXCR4 expression was reconfirmed in the present 
study (Table 3.8).  
Table 3.8: CT values of target genes (CXCL12 and CXCR4) and the housekeeping gene (HPRT1) by real-time 
PCR 
Cell line CXCL12 CXCR4 HPRT1 
DF-19 21.47 Not expressed 25.47 
FaDu Not expressed 31.30 23.47 
GR-145 27.35 Not expressed 25.01 
HaCat Not expressed Not expressed 24.79 
ZMK-1 Not expressed 22.95 22.58 
We examined, whether HNSCC tumour cells or control cells revealed characteristic CXCL12 
and CXCR4 patterns at protein levels. For this purpose, we performed western blot analysis 
and immunocytochemical staining. 
3.2.1.2 CXCR4 protein expression  
Western blot analysis was performed to assess CXCR4 protein expression in HNSCC and 





protein for each cell line were transferred from the TGX gels onto nitrocellulose membranes 
and incubated with primary antibodies specific for each protein of interest (CXCR4 and β-
actin). Appropriate secondary antibodies were used to detect specific binding of the primary 
ones. Due to the nearly identical molecular weight of CXCR4 and β-actin an extra blot was 
probed for β-actin as an internal control to ensure equivalent protein loading and also protein 
integrity (see Chapter 2.3.3). 
Western blot analysis of β-actin showed positive bands for all cell lines, indicating sufficient 
amounts of protein and successful transfer. As shown in Figure 3.11, the expression of 
CXCR4 was confirmed in two tumour cell lines, ZMK-1 and FaDu, with strong bands at a 
molecular weight of about 40 kDa, while GR-145, HaCat and DF-19 cell lines showed no 




Figure 3.11: Protein expression analysis of CXCR4 and β-actin (as internal control) in three 
HNSCC tumour and two control cell lines by western blotting.  These two blots were produced using 
TGX-gel. The gel was run at 200 V and 30 mA before being transferred to a nitrocellulose membrane 
following an appropriate transfer protocol for 3 minutes. Whole cell lysate probed against CXCR4 and 
β-actin showing lower CXCR4 expression in ZMK-1 cells than in FaDu cells, while GR-145, HaCat 
and DF-19 cell lines were negative. β-actin serves to control for equal protein loading, and is observed 





3.2.1.3 CXCL12 immunocytochemistry  
The presence of CXCL12 in the cells was studied by immunocytochemical staining. Figure 






Figure 3.12: Cells stained by ICC method to detect CXCL12 in three HNSCC tumour and two 
control cell lines.   Red staining correlates to the presence of CXCL12 and the nuclei are stained blue. 
Tumour cells of ZMK-1 (A) and FaDu (B) were CXCL12-free. Other tumour cell line, GR-145 (C) 
showed a weak cytoplasmic staining. From two control cell lines, HaCat cells (D) were CXCL12-free, 






Red staining correlates to the presence of CXCL12. Chemokine-free cells i.e. HaCat, FaDu 
and ZMK-1 show only blue stained nuclei. It can be seen that DF-19 cells expressed more 
CXCL12 in the cytoplasm, while a weak cytoplasmic staining in GR-145 cells was also 
observed (Figure 3.12, Tab. 3.9). 
The results of the PCR analysis, western blotting, and immunocytochemical staining are 
summarized in Table 3.9. 
Table 3.9: Review of CXCL12 and CXCR4 expression in each cell lines  
 
Cell line CXCR4 CXCL12 
ZMK-1 Positive (PCR, WB) Negative (PCR, ICC) 
GR-145 Negative (PCR, WB) Positive (PCR, ICC) 
FaDu Positive (PCR, WB) Negative (PCR, ICC) 
HaCat Negative (PCR, WB) Negative (PCR, ICC) 
DF-19 Negative (PCR, WB) Positive (PCR, ICC) 
3.2.1.4 Investigation of the radiosensitivity of the cell lines 
A colony-forming assay was performed to examine and compare the radiosensitivity of 
HNSCC tumour and control cells. Using the Kaleidagraph
®
 software, the surviving fractions 
(SF) of irradiated and treated/untreated cells in all performed experiments were determined 
and the means and standard deviations of the SF were calculated. In the colony-forming 
assay, the cell survival curve describes the correlation between the radiation dose and the 
fraction of cells still dividing. The response of all cell lines to increasing radiation doses is 
shown in Figure 3.13 A-D. The survival curves for the irradiated cells alone show that for all 
four cell lines exposure to increasing doses of radiation induces a proportional decrease in 
clonogenic cell survival (Figure 3.13 A-D, solid lines). 
The impact of CXCL12 and AMD3100 on the radiosensitivity of the cell lines was measured 









Figure 3.13: Surviving fraction of three HNSCC tumour and one control cell lines after 
irradiation alone or a combined treatment with 100 ng/ml CXCL12 after 0.5, 2, 4 and 6 Gy of 
radiation. After about 10 days, colonies were fixed and stained with 0.1% crystal violet solution. 
Colonies were counted and the surviving fraction was normali sed to the surviving fraction of the 
corresponding control. In all tumour and control cell lines, irradiation reduced cell survival in a dose-
dependent manner. The ZMK-1 cell line (A) (one of the CXCR4-positive cell lines) showed a 
significantly enhanced radiosensitivity in response to CXCL12 treatment , while GR-145 (B) and FaDu 
(C) cells showed a weak enhanced sensitizing effect of CXCL12. HaCat cells (D) were not affected by 






The radiosensitivity with a dose-modifying factor (DMS) of 1.44 was significantly increased 
in the ZMK-1 cell line, the tumour cell line that is negative for CXCL12 and has the high 
CXCR4 expression, when treated for 26 hours with CXCL12 (Figure 3.13-A). GR-145 cells 
and FaDu cells showed a slightly enhanced sensitizing effect of CXCL12 in the culture 
medium (Figure 3.13-B, C). However, HaCat cells were not affected by the addition of 
CXCL12 at all (Figure 3.13-D). Data were derived from three independent experiments and 
error bars show the standard error of the mean survival following exposure to 0.5, 2, 4, and 6 
Gy radiation. 
To determine the impact of the CXCR4 inhibitor, AMD3100, on the radiosensitivity of 
CXCR4-positive cell lines, cells were incubated with 5 µg/ml AMD3100 for 26 hours. After 
incubation, the colony-forming assay was performed (see Chapter 2.3.5.1). The data shown 
are the means and standard deviations of three independent experiments following exposure 
to 0.5, 2 and 4 Gy of radiation. FaDu and ZMK-1 cells were not affected by the addition of 
AMD3100 to the cell culture medium indicating that AMD3100 has no effect on the 
radiosensitivity of these CXCR4-positive tumour cell lines (Figure 3.14). 
 
 
Figure 3.14: Surviving fraction of two CXCR4-positive HNSCC tumour cell lines after 
irradiation alone or combined with 5µg/ml AMD3100 after 0.5, 2 and 4 Gy of radiation.  A) 
AMD3100 showed no effect on radiosensitivity of ZMK-1 (CXCR4-positive) tumour cell lines. B) 






3.2.1.5 Metabolic activity of the cell lines under different treatment  conditions 
3.2.1.5.1 Preliminary experiments 
First preliminary experiment 
In order to determine the optimal incubation times and effective radiation doses for all 
planned experiments the preliminary CTB assay procedure was performed as described in 
Chapter 2.3.6.1. First preliminary experiments were performed with incubation times of 26, 
48, 72 and 96 hours for ZMK-1 and HaCat cell lines (Figure 3.15). The viable cells can 
convert resazurin into resorufin, a highly fluorescent product. This intensity of the 






























































Figure 3.15 shows that a reduced viability of 4 Gy-irradiated ZMK-1 cells can been seen after 
a 96-hour incubation time, while HaCat cells would probably require a longer incubation time 
or a higher radiation dose to show alterations in metabolic activity.  
Second preliminary experiment 
A second preliminary experiment was performed to determine the optimal radiation dose. The 
incubation time for this second preliminary test was set at 72 hours after irradiation (see 
Chapter 2.3.6.1.).  
 
Figure 3.15: First preliminary CTB assay experiments with 26, 48, 72 and 96 hours incubation 
time for ZMK-1 and HaCat cell lines.  The incubation time, after which difference between the 
irradiated and non-irradiated cells was observable, was chosen as an optimal incubation time. A) In the 
ZMK-1 cell line a difference of metabolic activity of irradiated and non-irradiated cells was observed 
after 96 hours. B) In the HaCat cell line no impact of irradiation on cell viability was detected even 
after 96 hours incubation time. Each experimental condition was performed in triplicate. A total dose 






















Figure 3.16 illustrates that for the diverse radiation doses, no clear difference in cell viability 
of control cell lines, HaCat and DF-19, can be observed. The tumour cell line FaDu showed 
reduced metabolic activity following 6, 8, 10 and 12 Gy radiation, while the tumour cell line 
GR-145 showed slightly decreased cell viability only with 8 Gy irradiation (Figure 3.16). 
Third preliminary experiment 
In the final experiment, the number of cells in each well was reduced from 5000-6000 cells to 
2000 cells. The incubation time was prolonged to one week (168 hours) to analyse the cell 
viability in an expanded period of time and a radiation dose of 8 Gy was used. The results are 
summarised in Figure 3.17. There was only a non-significant reduction in the fluorescence 
 
Figure 3.16: Second preliminary CTB assay experiment with different radiation doses.  Cells were 
incubated for 72 hours. A) The tumour cell line FaDu (at 6 to 12 Gy) showed reduced cell viability 
compared to non-irradiated control cells after irradiation . B) The control DF-19 cell line showed 
reduced metabolic activity after 12Gy radiation . C) The tumour GR-145 cell line showed reduced cell 
viability compared to non-irradiated control cells after irradiation (only with 8Gy). D) In the HaCat 
cell line even after 12Gy radiation, the metabolic activity of the cells was still efficient. Each 
experimental condition was performed in triplicate. A total dose of 2, 4, 6, 8, 10 and 12 Gy was 





Figure 3.17: Optimising incubation time, radiation dose and cell densities in all used cell lines.  
The cells were irradiated with 8 Gy and after one week incubation time, the cell viability was 
measured. Each cell line except DF-19 demonstrates reduced metabolic activity following irradiation.  
Each experimental condition was performed in triplicate. A total dose of 8 Gy was delivered with a 






intensity in the DF-19 cells, while a notable reduction of fluorescence was detected in the 
other cell lines (Figure 3.17). In addition, between non-irradiated cells, the FaDu cells after 
one week incubation time showed more cell viability in compare to DF-19 cells.  
After optimising the parameters for analysing cell viability the results suggested that the 8 Gy 
irradiation dose with a one-week incubation time should be used to detect the impact of 
irradiation on cell viability.  
3.2.1.5.2 Main experiment: Analysis the cell viability of cells under different 
treatment conditions 
This aforementioned irradiation dose and incubation time (Figure 3.15-17) was used in the 
following CTB assay to determine the impact of CXCL12 and AMD3100 on the metabolic 
activity of each cell line.  
To this end, cell suspensions were prepared and the cells incubated with 100 ng/ml CXCL12, 
5 µg/ml AMD3100 or both for 30 minutes at 37°C and 5% CO2. The cells were pipetted in 
two 96-well plates (2000 cells/well). One of two plates was irradiated at 8 Gy. The cell 
viability of each cell line under the different treatment conditions was analysed after one 
week. The non-irradiated or untreated cells were compared using the t-test, and p<0.05 was 
regarded significant. In each group the cell viability in the presence of CXCL12, AMD3100 
or both compounds was compared with untreated cells. In addition, cells treated with 
CXCL12, AMD3100 or both and irradiated with 8 Gy were compared with non-irradiated 
cells to study the impact of irradiation on cell viability. Data are presented as mean 
differences ± standard deviations. Results are taken from two independent experiments, 
always performed in triplicate (Figure 3.18).  
Of all cell lines, tumour cell lines ZMK-1, FaDu and GR-145 were rather radiosensitive, and 
irradiation reduced viability as shown by the results of the colony-forming assays (Figure 3.18 
A-C). However, the metabolic activity of the control cell lines, DF-19 and HaCat, was not 
significantly reduced by irradiation (Figure 3.18 D-E). 
As seen in Figure 3.18, the tumour cell lines, ZMK-1, FaDu and GR-145 as well as the 
control cell line DF-19 showed unchanged cell viability following treatment with CXCL12, 





AMD3100 or even both together, there was a significant increase of metabolic cell activity 












3.2.2 The role of CXCL12 and CXCR4 in the migration of  HNSCC and control 
cells 
3.2.2.1 Preliminary experiments 
To determine the best concentration of CXCL12 for the lower chamber in the migration 






Figure 3.18: Mean fraction of viable cells of non-irradiated and 8 Gy irradiated cells. The cells were 
additionally pre-treated with either 100 ng/ml CXCL12, or 5 µg/ml AMD3100 or both compounds. A) ZMK-1 cells 
were radiosensitive and the metabolic activity of cells following treatment with CXCL12, AMD3100 or both 
compounds was not changed. B) FaDu cells were also radiosensitive and treatment with CXCL12, AMD3100 or 
both compounds was not changed the metabolic activity of cells. C) Irradiation reduced also viability of GR-145 
cells. Cells showed unchanged metabolic activity following treatment with CXCL12, AMD3100 or both 
compounds. D) The metabolic activity of HaCat cells was not reduced by irradiation. However, treatment with 
CXCL12, AMD3100 or both compounds showed an increased cell metabolic activity compared to the untreated 
control cells. E) Irradiation and treatment with CXCL12, AMD3100 or both compounds have no effect of metabolic 
activity of DF-19 cells. Student’s t-test was used in all experiments: *=p<0.05. The results were compared to non-
treated cells from each cell line. Data are obtained as mean differences ± standard deviation. Results are taken from 





chamber were 25, 50 and 100 ng per ml, respectively. After incubation, the migrated cells 
were stained, quantified, and the results compared to controls without addition of CXCL12.  
We observed a significant CXCL12-related stimulation of migration for ZMK-1 cells with 
concentrations of 25 ng and 100 ng per ml with 160% and 180% increase of cell migration 
compared to controls (Figure 3.19). For the main migration assay experiments, the 100 ng/ml 
CXCL12 concentration was chosen.  
 
 
Figure 3.19: Concentration-dependent migration of ZMK-1 cells along a CXCL12 gradient.  The 
highest percentage of migrating ZMK-1 cells compared to the control with 0 ng/ml CXCL12 was seen 
at a concentration of 100 ng/ml. The experiment was performed one time. 
In the next step, to determine the best concentration of AMD3100, two preliminary tests were 
performed. First, the cells were incubated with AMD3100 at different concentrations. They 
were then pipetted into the upper chambers, while 100 ng/ml CXCL12 was added to all lower 
chambers except for control chamber (Figure 3.20-A). After incubation, the migrated cells 
were stained, numerated, and the results compared with control cells.  
Figure 3.20-A shows that after AMD3100 treatment, the migratory capacity of ZMK-1 cells 
was reduced in a concentration-dependent manner up to 25 µg/ml AMD3100. The inhibition 
rate with AMD3100 at 1, 5, 12.5 and 25 µg/ml was 89%, 64%, 58%, and 58%, respectively. 












Figure 3.20: Concentration–dependent effects of AMD3100 on cell migration.  Percentage of 
migrated ZMK-1 cells compared to a control with 100 ng/ml CXCL12 and 4 Gy-irradiated cells. A) 
Inhibitory effect on migration with different concentrations of AMD3100 in non -irradiated ZMK-1 
cells. CXCL12 (100 ng/ml) was added to all lower chambers except for control chamber.  The migration 
of ZMK-1 cells was reduced in a concentration-dependent manner up to 25 µg/ml AMD3100. B) 
Inhibitory effect on migration with different concentrations of AMD3100 in 4 Gy-irradiated ZMK-1 
cells.  CXC12 (100 ng/ml) was added to all lower chambers. The migration of irradiated ZMK-1 cells 








To analyse the inhibitory effect of different concentrations of AMD3100 on irradiated cells, 
ZMK-1 cells were incubated with different concentrations of AMD3100, then the cells were 
irradiated at 4 Gy. After seeding, the cells were incubated. Migrated cells were stained, the 
number of migrated cells was determined and the results were compared with control cells 
irradiated at 4 Gy, which had been exposed to 100 ng/ml CXCL12 but not treated with 
AMD3100. Figure 3.20-B shows that after AMD3100 treatment, the chemotactic activity of 
irradiated ZMK-1 cells was reduced in a concentration-dependent manner up to 5 µg/ml. 
However, the inhibitory effect of AMD3100 on the migratory response of irradiated cells 
decreased at higher concentrations of AMD3100 (25 and 50 µg/ml). For the main 
experiments, a concentration of 5 µg/ml of AMD3100 was used. 
3.2.2.2 Migratory response of HNSCC and control cells with different level of 
CXCL12 and CXCR4 expression 
The CXCR4-positive cell lines, ZMK-1 and FaDu, migrated uniformly in response to 
CXCL12 with an optimal response at 100 ng/ml. For these cells, the CXCL12-mediated 
migration could be abolished by pre-treatment with the CXCR4-antagonist AMD3100. As 
expected, CXCL12 had no significant effect on the migration activity of the CXCR4-negative 
GR-145 and HaCat cell lines. The data are summarized in Figure 3.21 A-E and a 
representative picture of FaDu cells that migrated across the transwell membrane to the other 
side of the filter is shown in Figure 3.22 A-C. 
Pre-treating the CXCR4-positive cell lines in upper chamber with AMD3100 resulted in a 
significant decrease in relative migration. As shown in Figure 3.21-A and B in ZMK-1 and 
FaDu cell lines, respectively, AMD3100 effectively blocked CXCL12-induced migratory 
response in a dose-dependent manner.  
Non-irradiated and irradiated cells exhibited comparable migration patterns with a decrease at 
higher radiation doses (Figure 3.21 A-D), the radiation effect being less pronounced than the 
effect of CXCL12 and AMD3100. DF-19 cells, which are CXCR4-negative and express and 
secrete large quantities of CXCL12 served as controls. The results showed no change in their 
migratory activities towards CXCL12, and reduced migration ability was found after 

















Figure 3.21: Effect of irradiation, CXCL12 and AMD3100 on the migration of three HNSCC 
tumour and two control cell lines. CXCL12 was present in the lower well and migration of cells was 
induced by 100ng/ml CXCL12. The migration assay showed that the CXCR4-positive cell lines, FaDu 
(A) and ZMK-1 (B) migrated to CXL12 through the membrane in a dose-dependent manner. No 
CXCL12-induced migration enhancement was observed for GR-145 and HaCat, which are CXCR4-
negative cell lines (C, D).  After combined CXCL12+AMD3100 treatment, the CXCL12-mediated 
migration of ZMK-1 and FaDu cells was significantly inhibited in a radiation dose -dependent manner 













Figure 3.21: Representative membranes of FaDu migrated cells ; the blue-stained cells are those 
cells which migrated through the upper surface to the lower surface of the membrane.  The photographs 
of A) FaDu cells B) FaDu cells with CXCL12 (100ng/ml) in lower chamber C) AMD3100 (5µg/ml) 








4.1 Summary of results 
Besides tobacco and alcohol consumption being primary risk factors for the development of 
head and neck squamous cell carcinoma (HNSCC), infection with human papillomavirus 
(HPV) is also etiologically associated with a subgroup of cancers in head and neck regions 
(Gillison et al. 2000, Argiris et al. 2008). In the present retrospective study, the prevalence of 
HPV DNA was screened in tissue samples that had been taken from patients with HNSCC 
before therapy was started. Nested-PCR was used as a direct screening method to detect HPV 
DNA in 233 HNSCC pre-treatment formalin-fixed paraffin embedded (FFPE)-biopsies. Even 
though FFPE samples were comparably old, we were able to detect HPV DNA in 44 of the 
233 samples (19%). HPV-16, as a known dominant participant in HPV-positive HNSCC 
patients, was found in 95% of all HPV-positive samples. 
HPV-positive head and neck cancers are characterised by p16
INK4A
 overexpression, which is a 
consequence of retinoblastoma protein (pRb) inhibition by E7, one of the HPV oncogenes (Li 
et al. 1994). p16
INK4A
 expression was detected by immunohistochemistry (IHC) staining in 
102 of the 233 samples in this study (44%).  
The correlation between p16
INK4A
 expression and HPV DNA in tumour cells was highly 
significant (p<0.01); 41 of the 42 (98%) samples positive for HPV-16 also showed p16
INK4A
 
immunoreactivity. Because of the difficulties in detecting HPV DNA in old FFPE-biopsies 
and in view of the extremely significant correlation between HPV-positivity and p16
INK4A
 
overexpression, we used p16
INK4A
-positivity for further analysis. The clinicopathological 
analyses showed no statistically significant difference between patients with p16
INK4A
 
expression and those with no expression. However, positive p16
INK4A
 expression was 
correlated with better overall survival (OS) of patients (p = 0.022).  
Treatment of HNSCC is usually performed using surgery, radiotherapy (RT), and 
chemotherapy (CT) (Sayed et al. 2011). The combination of radiation and CT may cause 
acute organ and/or hematotoxicity. In terms of response to therapy, this treatment-related 
high-grade acute organ toxicity (HGAOT) plays an important role as positive prognostic 
factor for locally advanced, inoperable HNSCC patients treated with primary (Wolff et al. 





studied the impact of the combination of HGAOT as a potent prognostic marker in HNSCC 
and p16
INK4A
 expression as a known surrogate marker for HPV-positive HNSCC on the 
survival of patients. We were able to demonstrate that both parameters, p16
INK4A
 expression 
and the occurrence of HGAOT, are independent positive prognostic factors for the survival of 
patients with HNSCC treated with primary R(C)T. 
HNSCC is characterised by a high rate of early recurrence, the development of secondary 
primary cancers (Azad et al. 2012), and a high mortality rate. The CXCL12/CXCR4 axis has 
been suggested to play an important role in cancer metastasis (Crump et al. 1997, Kang et al. 
2005, Liang et al. 2010). In the present study we analysed the expression and prognostic 
significance of CXCL12 and its receptor CXCR4 in our cohort of 233 HNSCC patients. We 
observed that the expression of CXCL12 is directly correlated with tumour localisation 
(p<0.001) and the N-status (p=0.025) of the patients. However, patients with CXCL12 
expression had a significantly better chance of survival (p=0.036). On the other hand, CXCR4 
expression had a negative prognostic impact on distant metastasis-free survival (DMFS) 
(p=0.034). These results suggest that CXCR4 expression in HNSCC could be used as a 
biomarker for aggressive HNSCC tumours with high metastatic tendency.  
While the basic research and in vitro studies are the first step towards the elucidation of in 
vivo physiological processes, a one-to-one agreement between in vitro and in vivo results is 
not usually possible. In this study the importance of the CXCL12/CXCR4 axis in the 
migration of HNSCC cells was analysed, while taking into account the effects of irradiation. 
The cells were characterised for their viability, colony-forming ability, radiosensitivity and 
the degree of CXCL12 and CXCR4 expression. Through these in vitro analyses, we 
demonstrated a potentially important role of the CXCL12/CXCR4 axis in the promotion of 
migration of CXCR4-positive HNSCC cell lines even after irradiation, while AMD3100 
effectively blocked the CXCL12-induced migratory response in a dose-dependent manner in 
CXCR4-expressing cell lines (ZMK-1 and FaDu). These observations confirm a possible 









4.2 The crucial role of HPV/P16
INK4A
 in prognosis and survival of 
HNSCC patients 
4.2.1 HPV detection 
Analyses of molecular changes in HNSCC development have identified a new prognostic 
indicator, namely, HPV infection. The presence of HPV, particularly HPV-16, is of 
significant clinical importance, as these HPV-positive HNSCC tumours are associated with 
better clinical outcomes than their HPV-negative counterparts (Ragin and Taioli 2007, Fakhry 
et al. 2008). However, the reports on the incidence of HPV in oral carcinogenesis are 
contradictory with infection percentages ranging from 8% to 50%. This may depend on the 
different sensitivity of the applied methods, different sampling methods, the tissue 
preservation status, geographical differences or anatomic sites of infection (Miller and White 
1996, Sand et al. 2000). Moreover, the time period of analyses as additional factor should be 
considered. In this study, we found a significant increase of p16
INK4A
 expression (the 
surrogate marker of HPV infection) from 1992 to 2011 (p=0.00091). Chaturvedi et al. in their 
analyses in 271 oropharyngeal squamous cell carcinoma (OPSCC) patients from 1984 to 2004 
also found a significant increase of HPV prevalence over calendar time regardless of the HPV 
detection assay (Chaturvedi et al. 2011). 
The choice of a suitably sensitive method for detecting HPV DNA has become increasingly 
complex. In situ hybridisation, for example, is only able to detect HPV when there are more 
than 10 copies of viral DNA per cell and this method may lack the sensitivity to detect HPV 
DNA in oral squamous cell carcinoma (OSCC) tumours with low copy number of HPV 
(Miller et al. 1994). Southern blot, dot blot or reverse blot hybridisation, on the other hand, 
can detect even one copy of viral DNA per cell. PCR, a highly sensitive method, is able to 
detect even lower amounts than one copy of viral DNA per cell (Miller and White 1996). A 
meta-analysis by Termine et al. reported that the average HPV prevalence in OSCC published 
between 1988 and 2007 detected by in situ hybridisation was 29.8%, while PCR analysis 
resulted in a prevalence of 39.9% (Termine 2008). In the present study, we used a highly 
sensitive PCR-based analysis (nested-PCR) of viral DNA to detect HPV DNA. But even with 
this highly sensitive method (de Roda Husman et al. 1995, Ludyga et al. 2012) we only 
detected HPV DNA in 44 (19%) of the 233 FFPE-biopsies. Amplification in the nested-PCR 
was performed by two sets of primers with the combined sensitivity of the first and second 









al. 1995). This reduced the risk of missing any HPV-positive cases in our series. In the first 
step of nested-PCR using the PGMY09/11 primer set, we found no positive fragments, while 
in the second step using GP5+/6+ primers we did find positive ones. This result indicates that 
there are low numbers of intact copies of HPV DNA in our samples. Since the amplification 
efficiency of a genomic fragment is inversely related to the length of the region targeted by 
PCR, and additionally, in many archival samples, the amount of intact HPV genome is very 
small, the detection of the HPV DNA was impossible in some samples.  
Another important factor that influences detection of HPV DNA is tissue preservation. 
According to a meta-analysis by Miller and White, HPV DNA can be detected more often in 
fresh or frozen samples (51.6%) than in paraffin-embedded tissues (21.1%) (Miller and White 
1996). In this retrospective study we used FFPE blocks, which is a common way to preserve 
specimens for a longer time period. In spite of the many advantages of using formalin fixation 
to preserve tissues, it is known that formalin decreases the efficiency of PCR due to protein 
cross-linking (Karlsen et al. 1994, Williams et al. 1999). In addition, the degradation of 
nucleic acids increases during storage, in particular due to a time-dependent decrease of pH
 
(Gilbert et al. 2007). In addition, Ludyga et al. in their study of old FFPE tissue reported that 
fixation and storage conditions may make FFPE material unsuitable for further analysis 
because of the strong fragmentation of DNA (Specht et al. 2001, Ludyga et al. 2012).  
In 2005, Kreimer et al. published a meta-analysis of 60 eligible studies using PCR detection 
to study 5046 cases of squamous cell carcinoma (SCC), 2642 oral cancers, 969 oropharyngeal 
cancers and 1435 laryngeal cancers. They concluded that HPV-16 was the most common 
subtype in all types of HPV-positive cancers; 86.7% of oropharyngeal, 68.2% of oral and 
69.2% of laryngeal cancers (Kreimer et al. 2005). Rietbergen et al. also reported that after 
DNA and RNA analysis of 24 HPV-positive frozen oropharyngeal samples, HPV-16 was 
identified in 91.7% of the HPV-positive samples (Rietbergen et al. 2013). The present study 
came to results similar to those of the other studies. The sequencing analysis detected HPV-16 
as the clearly dominant (95%) subtype in the 44 HPV-positive HNSCC samples. 
In HPV-positive HNSCC, the production of the oncoprotein E7 induces the degradation of 
pRb, which in turn leads to p16
INK4A
 overexpression (Wiest et al. 2002, Marur et al. 2010). 
Furthermore, immunohistochemistry (IHC) positivity for p16
INK4A
 expression is considered to 
be one of the major molecular hallmarks of HPV-positive HNSCC (Hafkamp et al. 2008, 





off values to define positive p16
INK4A
 staining, but undisputed criteria do not exist (Deng et al. 
2014). For instance, in their study on FFPE tumour samples from HNSCC patients, Deng et 
al. evaluated the expression of p16
INK4A
 using a score of zero to four based on the percentage 
of p16
INK4A
-positive cells (Deng et al. 2014). In a study by Reimers et al., a strong nuclear or 
cytoplasmic staining was considered positive for p16
INK4A 
expression (Reimers et al. 2007). In 
this study, we assigned a weighted score to each case by multiplying the percentage of 
p16
INK4A
 positive cells (0-100%) by the staining intensity (0-3) and used the score values as a 
continuous variable in the Cox regression model. We detected a positive p16
INK4A
 expression 
in 102 (44%) of the samples. We also found 30 samples with strong and diffuse p16
INK4A
 
expression with undetectable HPV DNA. These results must be interpreted within the context 
of the study’s limitations. The source of high levels of p16
INK4A
 expression in some HPV-
negative tumours has not been clarified yet; mutations leading to p16
INK4A
 overexpression, 
other mechanisms of inactivation of retinoblastoma pathways or other viral infections are 
plausible alternatives. In this study, HPV DNA was amplified with the L1 consensus HPV 
PGMY09/11 and GP5+/6+ primer sets. The probability of a false negative HPV-L1-ORF due 
to the loss or disruption during integration of the HPV genome is another explanation for 
HPV DNA-negative, but p16
INK4A
 expression-positive cells (Duray et al. 2011). However, 
such a discrepancy between positivity of HPV and p16
INK4A
 expression is not uncommon 
(Blitzer et al. 2014). In this study, eighteen of the thirty p16INK4A expression-positive/HPV 
DNA-negative samples (60%) revealed either poor quality or small quantity (< 20ng/µl) of 
extracted DNA, which did not reach the threshold of 1.8 (OD 260/280) as a measure of DNA 
quality.  
On the other hand, 95% (42 of 44) of HPV-positive HNSCC tumours were found to 
overexpress p16
INK4A
. Of this set, only one high-risk HPV-positive tumour was negative for 
p16
INK4A
 expression. We also had one sample that was infected with low-risk HPV-6 and did 
not show p16
INK4A
 expression. It could be argued that viral oncoprotein of low-risk HPV such 
as HPV-6 have no effect on p16
INK4A
 expression because the affinity of HPV-6 E7 protein for 
cellular pRb is 10-fold lower than that of E7 oncoprotein of HPV-16 as high-risk HPV 
subtype for pRb (Gage et al. 1990).  
Because of the low number of patients, in whom HPV DNA was detected and the significant 
correlation between HPV positivity and p16
INK4A
 overexpression, we used p16
INK4A
 positivity 








status kept its prognostic significance even in the absence of concomitant HPV DNA 
detection in several studies (Weinberger et al. 2006, Lassen et al. 2009, Shah et al. 2009, 
Harris et al. 2011). Kawakami et al. in their study on Japanese patients with OPSCC even 
reported that the survival of patients with HPV DNA-positive/p16
INK4A
-negative tumours was 
not as high as that of those with HPV DNA-positive/p16
INK4A
-positive tumours (Kawakami et 
al. 2013). In this study, we found a significant correlation between the p16
INK4A
-positive 






-associated HNSCC and prognosis of patients 
In HPV-associated malignancies, particularly in OSCC and OPSCC, most studies revealed a 
more favourable prognosis in terms of recurrence-free survival and OS in patients with a 
HPV-positive tumour compared to those whose tumours were HPV-negative (Lindel et al. 
2001, Li et al. 2003, Lindquist et al. 2007). In agreement with three previous studies, Young 
and colleagues in their study of 131 pre-treatment FFPE OPSCC tissue samples showed that 
p16
INK4A
-positive patients had a significantly improved failure-free survival (FFS) and OS 
compared to p16
INK4A
-negative patients (Young et al. 2011). Recent analysis of clinical data 
revealed that using p16
INK4A
 expression as a surrogate biomarker in HPV-positive HNSCC 
patients has a significant impact on treatment response and survival in HNSCC patients and 
also has a stronger prognostic value than the HPV status (Weinberger et al. 2006, Zhao et al. 
2012, Dok et al. 2014). In another study, Lassen et al. indicated that HNSCC patients with 
p16
INK4A 
expression showed a better response to RT and also an improved locoregional 
control rate than patients without p16
INK4A 
expression (Lassen et al. 2009). We also found a 
close association between p16
INK4A
 expression in HNSCC tumours and better OS (p=0.0022). 
However, the improvement of local recurrence-free survival (LRFS) in patients with p16
INK4A
 
expression was not statistically significant (p = 0.069, Figure 3.10). Because patients with 
oropharyngeal tumours benefit most from p16
INK4A
-positivity and have better three-year 
recurrence-free survival (Deng et al. 2014), the combined analysis of tumours located in the 
oropharynx, hypopharynx, oral cavity, and larynx may explain the lack of a significant 
correlation of p16
INK4A 
-positivity with LRFS in the present study. 
The reason for the improved survival of HNSCC patients positive for p16
INK4A
 expression has 





onset, or have a lower exposure to established risk factors such as tobacco and alcohol 
consumption (Lassen et al. 2009). In addition, improved responsiveness to RT, enhanced 
immune surveillance and the absence of field cancerisation in the patients who tend to be non-
smokers, have been reported (Lindel et al. 2001, Mellin Dahlstrand et al. 2005, Fakhry and 
Gillison 2006). McGovern et al. also stated that they had not observed a field cancerisation 
effect in HPV-positive tumours, where HPV viral DNA integration is solely restricted to the 
neoplastic and dysplastic tissue (McGovern et al. 2010).  
Radiation-induced DNA damage prompts apoptosis in tumour cells (Lima et al. 2012). A 
possible explanation for tumour radio-resistance may be a failure in DNA damage repair 
pathways, cell cycle checkpoints, as well as mechanisms of apoptosis (Xu et al. 2008). 
Increased radiation sensitivity of p16
INK4A
-positive tumours, possibly caused by reduced 
ability of cells to the normal cellular response to DNA damage, compromised DNA repair 
capacity or an altered oxygenation status (Kessis et al. 1993, Kong et al. 2009, Rieckmann et 
al. 2013, Dok et al. 2014) may account for the greater survival rate of patients with p16
INK4A
-
positive tumours. Recently, Kimple and colleagues observed an increased level of apoptosis 
and low levels of intact p53 after irradiation in HPV/ p16
INK4A
-positive HNSCC cells, which 
could be activated by RT (Kimple et al. 2013). They also verified that HPV-positive cells in 
head and neck cancer show increased radiosensitivity. Their results from in vitro and in vivo 
studies explained this effect with prolonged activation of markers of DNA damage, E6/E7-
mediated radiation-induced G2 arrest, and a strong apoptotic response and enhanced cell death 
(Kimple et al. 2013). However, existing data so far are questionable and at times 
contradictory (Bol and Gregoire 2014). It seems to be a complex interaction between basic 
mechanisms of radioresponse and the microenvironment of the tumour such as cells of the 
immune system (Bol and Gregoire 2014). In HPV-positive HNSCC tumour infiltration seems 
to play a significant role, leading to some studies suggesting that TR promotes immunogenic 
cell death led by T-cells in HPV-positive HNSCC (Kong et al. 2009, Bol and Gregoire 2014). 
4.2.3 Combined effect of p16
INK4A
 expression and the occurrence of HGAOT on 
patients’ survival  
In a previous clinical study, HPV-positivity in HNSCC patients was associated with a 
superior response to RT and RCT and modality-independent survival benefits (Boscolo-Rizzo 





HPV-related HNSCC have already led to clinical studies that investigate de-intensified 
treatment schedules (Psyrri et al. 2014). Based on some studies, which consider that intensive 
RCT in HPV-positive patients may represent over-treatment (Forastiere 2008, Mannarini et 
al. 2009), and in view of the fact that HPV-positive patients are often younger and have a 
better prognosis (Kofler et al. 2014), the question of aggressive combined treatment, which is 
associated with high rates of acute or late toxicity of the therapy, has become an important 
issue (Boscolo-Rizzo et al. 2013).  
Generally, HNSCC patients undergoing radiation therapy may suffer from a number of side-
effects, above all from organ toxicity. Nevertheless the severity of organ toxicity may vary 
between patients, as does the course and outcome of the disease. In this respect Bonner et al. 
showed that in patients with locally advanced HNSCC who were treated with RT and CT, 
acute rash and skin toxicity were correlated with a significantly better OS (Bonner et al. 
2005). In another study on HNSCC patients, Wolff et al. suggested that normal tissue and 
tumour tissue might behave similarly with reference to treatment response (Wolff et al. 
2010a, Wolff et al. 2011b). Their investigation on the association between HGAOT during 
definite primary and adjuvant radiation and chemotherapy and the treatment outcomes in 
patients with locally advanced HNSCC showed that occurrence of HGAOT during or after 
therapy was associated with better outcomes, i.e. a better five-year OS and locoregional 
control rate of patients (Wolff et al. 2010a, Wolff et al. 2011b). This association of HGAOT 
and improved OS for patients, suffering from HGAOT, is mentionable. 
Much too little is known about the detailed molecular biological mechanisms and causes for 
the significant correlation between HGAOT and the OS improvement (Wolff et al. 2010a, 
Wolff et al. 2011b). This behavioural similarity between normal and tumour tissues with 
regard to treatment response might be explained by inter-individual differences in inherent, 
genetically determined sensitivity (Wolff et al. 2010a). An association between the 
appearance and maintenance of inflammatory mediator proteins that can cause acute organ 
toxicity, and an improved patient outcome has already been defined in the course of other 
studies (Galon et al. 2013) in contrast to other studies which showed that chronic 
inflammation promoted tumour progression (Trinchieri 2012). Moreover, the induction of a 
cytokine cascade in the acute reaction in normal and tumour tissues as a local factor might 
also be involved (Wolff et al. 2010a, Wolff et al. 2011b). The correlation between HGAOT 
and better treatment outcomes is not only limited to HNSCC patients. In breast cancer, Kuhnt 





erythema, dysphagia, or pneumonitis, and who were treated with post-mastectomy RT, 
showed a trend towards better local control rates (Kuhnt et al. 1998). In anal carcinoma, 
patients with HGAOT treated with primary radiation and chemotherapy also showed better 
OS (Wolff et al. 2010c). In another study in patients with locally advanced rectal cancer, a 
statistically significant association was reported between HGAOT during preoperative 
radiation and chemotherapy and a complete histopathological tumour regression after total 
mesorectal excision in multimodal treatment (Wolff et al. 2010b).    
In the present study, we retrospectively investigated the correlation between p16
INK4A
 
expression and the occurrence of HGAOT in patients, who were treated with definite R(C)T. 
The univariate analyses showed an association between HGAOT and p16
INK4A
 expression 
(p=0.011, Figure 3.6-F). Patients with p16
INK4A
-positive tumours demonstrated significantly 
more HGAOT than patients with p16
INK4A
-negative tumours. Mucositis and dysphagia are the 
observable manifestations of acute organ toxicity as side-effects of the R(C)T.  
Since the present study confirmed the well-known association of p16
INK4A
-expressing tumours 
with an improved OS of patients (Weinberger et al. 2006, Lassen et al. 2009, Shah et al. 
2009, Blitzer et al. 2014), and also the formerly described correlation of OS with occurrence 
of HGAOT in patients with HNSCC (Wolff et al. 2010a, Wolff et al. 2011b), we investigated 
the impact of a combination of these two factors on the survival of patients. However, since 
multivariate analysis revealed no significant interaction between p16
INK4A
-expressing tumours 
and the occurrence of HGAOT, which could suggest additive effects of these two parameters, 
they were identified as independent prognostic factors. Such combined impact of two 
parameters is reflected by the five-year OS rates of 47%, for patients with p16
INK4A
 expression 
and HGAOT, compared with 42%, 20%, and 10% for patients with HGAOT only, patients 
with p16
INK4A
 expression only, and patients without either p16
INK4A
 expression or HGAOT, 
respectively (Figure 3.10). Interestingly, the dominant survival effect of p16
INK4A
 expression 
was more evident in patients without any or with only mild acute organ toxicity ≤ grade 2 
CTC. Based on these results, we believe that the analysis of HGAOT of patients during 





4.3 Analysis of the prognostic roles of CXCL12 and CXCR4 
Technological advance and scientific research provided valuable information on the cellular 
and molecular mechanisms that underlie tumour progression and treatment response. The 
chemokine CXCL12 and its receptor CXCR4 play a role in several types of tumours and 
promote tumour progression, angiogenesis and metastasis (Popple et al. 2012). An association 
between CXCL12 expression and better treatment outcomes and improved OS has also been 
reported in carcinomas of the breast (Kang et al. 2005), the ovaries (Jiang et al. 2006), the 
oesophagus (Sasaki et al. 2008), the stomach (Ishigami et al. 2007), as well as gliomas 
(Salmaggi et al. 2005). In addition, increased expression of CXCR4, the main receptor of 
CXCL12, was reported to a have a prognostic value for patients with renal, colorectal, and 
breast carcinoma (D'Alterio et al. 2010, Hiller et al. 2011, Parker et al. 2012, Yopp et al. 
2012). Since a high expression of CXCL12 and CXCR4 in various types of cancer predicts 
poor patient outcomes, the analysis of their expression levels may have an important 
prognostic value (Maréchal et al. 2009, Bennani-Baiti et al. 2010, Wu et al. 2010, Jung et al. 
2011, Ramos et al. 2011, Wang et al. 2011, Popple et al. 2012, Zhang et al. 2013). In the 
present study, we investigated expression of CXCL12 and CXCR4 as novel prognostic factors 
for HNSCC patients treated with definite R(C)T. The levels of the two proteins were 
independently related to clinicopathological characteristics and survival data of the patients. 
One significant advantage of this retrospective study was the long follow-up times of up to 
217 months (median 83 months), which provided reliable survival data. Using IHC, we 
detected expression of CXCL12 in 41.6% and of CXCR4 in 66.1% of the 233 biopsies taken 
from HNSCC patients before the beginning of the treatment. In a similar analysis by Almofti 
et al., the expression of CXCL12 and CXCR4 in biopsy specimens from 61 patients with 
OSCC assessed by IHC was 11.4% and 57.3%, respectively (Almofti et al. 2004). In another 
study by Ishikawa et al., expression of CXCR4 was detected by IHC in 30% of the 90 OSCC 
tissue samples (Ishikawa et al. 2006). Although we were unable to find a significant 
association between the expression of CXCR4 and any clinicopathological features, we did 
find a statistically significant correlation between the expression of CXCL12 and N-staging 
(p=0.025, Table 3.2). Despite this association, we found that these patients had significantly 
better OS, which confirms the results of Clatot et al., who also found a significant association 
between the CXCL12 expression level and metastatic evolution and OS in a series of 71 
OSCC patients (Clatot et al. 2011). Moreover, in a gene expression study conducted by these 





with the better prognosis showed higher expression levels of genes involved in the CXCL12 
pathway. It should be noted that observations from experimental studies also support the 
clinical evidence of improved prognosis in patients with a high level of CXCL12 expression. 
Roy et al. in in vitro and in vivo studies on pancreatic cancer cell lines and tumour tissues also 
observed that autocrine CXCL12 expression reduced the growth and migration potential in 
vitro, and also reduced growth and metastasis rate of pancreatic ductal adenocarcinoma cells 
in vivo (Roy et al. 2014). 
The superior OS of patients, whose tumours expressed CXCL12, may be explained by the 
experimental findings from other studies that described the suppression of tumour cell 
migration, reduced tumour growth potential, modified radio- and chemosensitivity, or an 
enhanced immune response (Williams et al. 2010, Albert et al. 2013, Clatot et al. 2014, Roy 
et al. 2014). Granot et al. and Williams et al. demonstrated that the activation of functional 
CD8
+
 T cells or neutrophils may modulate the immune response, which leads to the inhibition 
of metastasis and tumour progression (Williams et al. 2010, Granot et al. 2011). However, 
CXCL12 is able to induce different anti-tumour responses depending on the tumour type 
(Williams et al. 2010). For instance, Fushimi et al.  demonstrated that CD8
+ 
T cells play an 
important role in the inhibition of the CXCL12-mediated growth of melanoma and lung 





 T cells were required. In this study, all of the CD4
+
-depleted animals developed 
lethal tumours, while this occurred in only 20% of the CD8
+
-depleted animals (Dunussi-
Joannopoulos et al. 2002). In HNSCC patients treated with definite RCT, Balermpas et al. 





lymphocytes and improved OS and DMFS (Balermpas et al. 2014). Taken together, CXCL12 
is a chemokine with a wide spectrum of immunoregulatory properties and tissue specific 
CXCL12/CXCR4 interactions, and further studies of these mechanisms may lead to novel 
therapeutic strategies. 
The expression of CXCR4 is reported in diverse tumour entities. Moreover, many studies 
have shown an association between CXCR4 expression and a worsening of the OS because of 
a rapid tumour recurrence and metastasis (Iwakiri et al. 2009, Wagner et al. 2009, Otsuka et 
al. 2011). In this study, multivariate analysis showed a significant correlation between high 
CXCR4 expression and a reduced DMFS. Katayama et al. analysed 56 Japanese patients with 





metastases as well as a poor prognosis and poor survival rate (Katayama et al. 2005). In 
another study in OSCC patients by Lee et al., the association between CXCR4 expression and 
poor survival rate was also reported (Lee et al. 2009). The causes for an increased CXCR4 
expression in HNSCC and the relation to increased metastasis and reduced metastasis-free 
survival of patients are ascribed to various factors. CXCR4 expression is enhanced in cells 
that exhibit biological and morphological modifications associated with an epithelial-to-
mesenchymal transition (EMT) (Yoon et al. 2007, Taki et al. 2008).  Ou et al. also found an 
association between CXCR4 expression and lymph node metastasis, and the authors suggest 
that the EMT-related critical transcription factor Twist might regulate expression of CXCR4 
especially during lymph node metastasis (Ou et al. 2008). In addition, Taki et al. 
demonstrated that CXCR4 was up-regulated in OSCC by CXCL12 and TGF-beta1 (Taki et al. 
2008). They also reported that overexpression of SNAIL, another EMT-promoting 
transcription factor induced overexpression of CXCL12 (Taki et al. 2008). Hypoxia is another 
important CXCR4-regulating factor in HNSCC. Certain tumour environmental factors such as 
hypoxia-inducible factor-1 (HIF-1) may directly induce the enhanced expression of CXCR4 
(Ishikawa et al. 2009). HIF-1 as a heterodimeric transcription factor responds to oxygen 
concentration in tissues and up-regulates CXCR4 expression. However, overexpression of 
HIF-1 is also known as a good indicator for a poor response to CRT in osteosarcoma or bone-
metastases (Huang et al. 1998, Bendinelli et al. 2013).  
Clinical and experimental studies revealed an association between CXCR4 expression and 
tumour cell migration or tumour metastasis. The strategic blocking approach to inhibit the 
CXCL12/CXCR4 pathway has focused on inhibitors of CXCR4 (CXCR4 antibodies or 
CXCR4 antagonist) or CXCL12. The anti-CXCR4 antibody, MDX-1338 is a novel drug 
candidate, which could directly block the interaction between CXCR4 and its ligand CXCL12 
and also inhibits CXCL12-induced cell migration (Kuhne et al. 2009, Ramsey and McAlpine 
2013). AMD3100, a well-known CXCR4 antagonist, which is currently being investigated in 
phase I/II trials, binds to CXCR4 and effectively blocks CXCL12 binding (Domanska et al. 
2013). Furthermore, AMD3100 is an attractive drug candidate for several cancers in which 






4.4 Migration of HNSCC cell lines along a CXCL12 gradient  
4.4.1 Characterisation of the employed cell lines 
We used an in vitro approach to study the role of CXCL12 and CXCR4 in the migration of 
HNSCC cell lines. Three HNSCC cell lines from two different anatomical subsites of head 
and neck regions with different CXCL12 and CXCR4 expression patterns were used. To 
avoid the impact of unexpected factors on the results of this analysis, we precisely 
characterised the expression of CXCL12 and CXCR4 at the mRNA and the protein level, the 
radiosensitivity of each cell line, a possible enhancement or reduction of radiosensitivity by 
CXCL12 and AMD3100 treatment, and at last the enhancing or inhibiting effect of CXCL12 
and AMD3100 on the proliferative capacity of the cell lines. 
We analysed the expression of CXCL12 and CXCR4 at the mRNA and protein level in three 
tumour (ZMK-1, FaDu and GR-145) and two control cell lines (HaCat and DF-19) by real-
time PCR, western blot and immunocytochemical staining. Our data showed that ZMK-1 and 
FaDu cells express CXCR4 and GR-145 and DF-19 cells express CXCL12 at both the mRNA 
and protein level. These results also confirmed the results of Wolff et al., who analysed the 
expression of several chemokines and chemokine receptors in HNSCC cell lines at the mRNA 
level (Wolff et al. 2011a). 
To determine the effect of CXCL12 and AMD3100 on HNSCC tumour cell radiosensitivity 
and clonogenic survival, we treated cells with CXCL12 or AMD3100 during colony-forming 
assay. In the present study, our experimental data showed an influence of CXCL12 on tumour 
cell radiosensitivity that was cell line-dependent. We found this CXCL12-related 
radiosensitisation in the tumour cell line ZMK-1 with the highest CXCR4 expression and no 
CXCL12 expression. To our knowledge no comparable experiments addressing the influence 
of CXCL12 on the cellular radiosensitivity have been conducted to date. However, Muller et 
al. showed that CXCL12 suppressed the rate of cisplatin-induced apoptosis in adenoid cystic 
carcinoma, a rare malignant epithelial tumour of the salivary glands (Muller et al. 2006). This 
CXCL12 stimulation resulted in the activation of AKT, ERK1/2, and MAP kinase pathways, 
which are commonly associated with cell survival and proliferation (Chan et al. 1999, Roux 





We found in all of the tumour cell lines (ZMK-1, FaDu and GR-145) and in one control cell 
line (HaCat) a reduction in clonogenic cell survival following exposure to increasing radiation 
doses. The second control cell line (DF-19) was not suitable for the colony-formation assay. 
Although the colony-forming assay is a broadly used technique, the results may be misleading 
under certain circumstances, when using primary (non-immortalised) cells. On the one hand, 
cells may be viable and able to divide very efficiently and still may not form colonies very 
well. On the other hand, non-immortalised cells are subject to replicative senescence after a 
number of population doublings (Ulus-Senguloglu 2012). At this point, the cells are 
metabolically viable but unable to undergo further cell division and are accordingly non-
clonogenic. This was confirmed for the DF-19 fibroblasts by viability assay. 
Do carmo et al. demonstrated that CXCL12 induced a significant increase in the proliferation 
of a CXCR4-positive glioma cell line (do Carmo et al. 2010). However, the effect of CXCL12 
on induction of glioma cell proliferation in a study by Zhou et al. was in disagreement. Zhou 
et al. showed that there was no association between treatment with CXCL12 and the 
proliferative potential of CXCR4 expressing cell lines (Zhou et al. 2002).  
Most studies investigating the biological function of CXCR4 and CXCL12 used AMD3100 as 
an efficient and specific CXCR4 antagonist that inhibits CXCL12-mediated calcium 
mobilisation, chemotaxis and GTP binding (Rubin et al. 2003, Marchesi et al. 2004, Cabioglu 
et al. 2005, Ohira et al. 2006, Burge and Peled 2009). Kim et al. reported that AMD3100 in 
high concentrations stimulates the proliferation of myeloma cells as compared to controls 
(Kim et al. 2010). They observed an initially enhancing and subsequently inhibiting effect on 
the survival and proliferation of myeloma cells as compared to controls. They also reported 
comparable observations in one leukaemia cell line (Kim et al. 2010). To investigate the 
metabolic activity-enhancing/reducing effect of CXCL12 and AMD3100 and irradiation on 
HNSCC tumour and control cell lines, we analysed the cell viability of the treated cells after a 
one-week incubation period. Cells were treated for 30 minutes with CXCL12, AMD3100 or 
both, before irradiation and one week of incubation. The same experimental set was 
performed with non-irradiated cells. Although some observations have shown that CXCL12 
or AMD3100 alters the proliferation of some cells in culture, our findings showed that 
treatment with either CXCL12, AMD3100 or both, had no enhancing or inhibiting effect on 
the cell proliferative capacity of all tumour cell lines (ZMK-1, FaDu, and GR-145) for up to 
one week. DF-19 was non-responsive as well, while in the second control cell line (HaCat) 





incubation with CXCL12 or AMD3100 did not considerably decrease the viability of HNSCC 
tumour cell lines, as expected, irradiation significantly reduced cell viability of the tumour 
cells. 
4.4.2 Effect of irradiation on the migration behaviour of HNSCC and control 
cell lines among a CXCL12 gradient 
Migration and invasion of tumour cells are chemokine-dependent. Müller et al. have 
demonstrated organ-specific metastases of breast cancer cells, which were directly associated 
with CXCL12 (Müller et al. 2001). They found that primary breast cancer tumours highly 
expressed CXCR4, whereas the peak level of CXCL12 mRNA expression was in organs that 
are preferential target organs of breast cancer metastasis (Müller et al. 2001). There is 
growing evidence supporting the crucial role of CXCR4 in promoting migration and 
metastasis of primary tumour cells to strongly CXCL12-expressing tissues (Burger et al. 
1999, Geminder et al. 2001, Müller et al. 2001, Robledo et al. 2001, Taichman et al. 2002, 
Ishikawa et al. 2006). In the present study, we investigated whether CXCL12 induced 
HNSCC cell migration with different CXCL12 and CXCR4 expression profiles. Since, no 
studies have analysed cell migration along a CXCL12 gradient in irradiated cells, we 
investigated the effect of irradiation on the migratory capacity on HNSCC cell lines, 
particularly CXCR4-positive cell lines. For cells responsive to CXCL12, an increased cell 
migration was observed at all radiation doses tested. As described above, CXCR4 contributes 
to a more aggressive metastatic phenotype (Albert et al. 2013), which could in part be 
associated with an enhanced migratory capacity of CXCR4-expressing tumours as we 
observed in CXCR4-expressing HNSCC tumour cell lines, ZMK-1 and FaDu. 
To answer to the question, whether CXCR4 expressed in CXCR4-positive HNSCC tumour 
cells is functionally active upon CXCL12 binding, we analysed the migration tendency in the 
presence of AMD3100. The significant reduction of cell migration in the CXCR4-expressing 
tumours cells, ZMK-1 and FaDu, by treatment with the antagonist AMD3100 was observed in 
both non-irradiated and irradiated cells in a dose-dependent manner. With regard to these 
results, it is conceivable that the combination of RT and AMD3100 may significantly reduce 
the migration potential of CXCR4-positive HNSCC cells. In this study, we showed the crucial 





of the blocking CXCR4 antagonist, AMD3100 on CXCR4-expressing HNSCC tumour cell 
lines. 
4.5 Future directions 
The incidence of HPV-negative HNSCC will probably continue to decline due to the trend to 
less smoking during the past decades. However, with the increased incidence of OPSCC with 
HPV positivity or the combination of tobacco and HPV infection it is conceivable that HPV 
will eventually become the main aetiology of head and neck cancer (Friedman et al. 2014). 
Because the two different tumour classes have different prognoses, treatment outcomes and 
survival rates, it will be important to follow the incidence of both HPV-positive and HPV-
negative HNSCC in the future. Moreover, further insights into the molecular alterations 
underlying HPV-induced carcinogenesis will provide valuable opportunities to recognize 
more effective selected pathways (Mirghani et al. 2014).  
Despite the improved clinical outcome for the majority of patients with HPV-positive 
HNSCC, the trend to reduce the used intensified treatment is growing and the necessity for 
less toxic therapies is seriously debated. The question for patients with positive HPV is not 
how to reduce the intensity of treatment, but how to optimize the treatment to these HNSCC 
tumours. It should be necessary to study further indicators or biomarkers that are able to 
distinguish which tumour is sensitive to a specific therapy intervention. 
CXCL12 and CXCR4 have been involved in organ-specific metastases of several tumour 
entities. The association between inferior DMFS and a high CXCR4 expression level may be 
useful in estimating the prognosis and identifying patients who would profit from intensified 
surveillance and additional or altered treatment. 
Our findings suggest that the inhibition of CXCL12 and CXCR4 by AMD3100 in HNSCC 
should be confirmed in vivo in order to evaluate the potential of CXCR4 as a therapeutic 
target in the treatment of HNSCC. Inhibition of the CXCL12/CXCR4 axis may have a 
positive impact on regulating tumour motility and organ-specific metastasis.  
Despite significant advances in the field of both HPV and the CXCL12/CXCR4 axis, we still 
need more research into HNSCC before individualised patient treatment becomes routine. 
Moreover, finding other biomarkers or prognostic indicators is very important to predict or 





this study will provide a rational basis for the further development of HPV, CXCR4 and 





5. Conclusion  
p16
INK4A
 expression is an important, independent prognostic marker in HNSCC patients. We 
observed a strong correlation between tumour HPV status, particularly HPV-16, and p16
INK4A
 
expression. Accordingly, our data clearly revealed that p16
INK4A
 expression may be a more 
powerful marker for predicting prognosis than HPV DNA detection from archived FFPE 
tumour tissues (Tehrany et al. 2015). The improved OS seen in HNSCC patients with positive 
p16
INK4A
 expression are thought to be independent of the treatment approach (Fakhry et al. 
2008, Worden et al. 2008, Lassen et al. 2009, Posner et al. 2011, Cmelak 2012). However, in 
this study we found that the combination of HPV/p16
INK4A
 positivity and HGAOT as 
treatment-related toxicities may have an additional effect on improved treatment outcomes 
and OS of HNSCC patients (Tehrany et al. 2015). Morover, p16
INK4A
 expression is more 
important for patients without HGAOT. For clinicians, the combined IHC report of  p16
INK4A
 
expression from the pathology laboratory and the analysis of acute organ toxicity of patients 
during therapy or even seen after therapy at follow-up appointments could provide important 
prognostic information for the individual patient and also become the basis of treatment 
decisions in the future. 
In this study, we presented clinical and experimental data, underscoring the prognostic value 
of CXCL12 and CXCR4 in HNSCC patients treated with R(C)T. immunohistochemical 
analysis of HNSCC biopsies showed that the expression of CXCR4 alone in tumour tissue 
was a negative predictor for patients, while the expression of CXCL12 was associated with 
improved OS. We evaluated CXCR4 as a predictive indicator for HNSCC patients with poor 
prognosis with regard to reduced DMFS and also investigated its biological relevance in the 
migratory capacity of HNSCC tumour cell lines in a CXCL12 gradient. CXCL12 had a 
specific effect on migration of HNSCC cells that does not stem to enhanced proliferation. 
Additionally, we were able to show that CXCL12 also induces irradiated HNSCC cells to 
migrate, whereas this tendency was significantly reduced in a dose-dependent manner by 
irradiation. As shown by an experiment in the in vitro study, CXCR4 significantly induces the 
migration of CXCR4-positive tumour cells and promotes the progression of distant metastases 
in our in vivo analysis. Accordingly, these results indicate that the CXCL12/CXCR4-pathway 
is functionally relevant in head and neck cancer cell lines, which in turn supports the clinical 





In conclusion, we have demonstrated that different indicators and biomarkers are of 
independent prognostic value in HNSCC. These results can also lead us to a new efficient 
treatment strategy, in which the intensity of CT or extent of the irradiated area can be altered 
while maintaining good tumour control with the ability to rationally personalise therapy to 
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